Date,Articles
2014-03-10,"{""abstract"": ""Minerals Technologies agreed to pay about $1.7 billion, beating out Imerys of France, after a spirited back-and-forth for Amcol, a producer of specialty minerals and materials based in Illinois."", ""web_url"": ""https://dealbook.nytimes.com/2014/03/10/minerals-technologies-wins-bidding-war-for-amcol-international/"", ""snippet"": ""Minerals Technologies agreed to pay about $1.7 billion, beating out Imerys of France, after a spirited back-and-forth for Amcol, a producer of specialty minerals and materials based in Illinois."", ""lead_paragraph"": ""LONDON \u2013 Minerals Technologies said on Monday that it had won a bidding war for Amcol International, agreeing to pay about $1.7 billion."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-jumbo.png"", ""height"": 246, ""width"": 354, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-superJumbo.png"", ""height"": 246, ""width"": 354, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbStandard.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbStandard.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/03/10/business/dbpix-amcol/dbpix-amcol-thumbLarge.png"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Minerals Technologies Wins Bidding War for Amcol International"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Top Suitor Wins"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Amcol International"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cravath Swaine & Moore"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Imerys SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Kirkland & Ellis"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Lazard LLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Minerals Technologies Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""France"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Illinois"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2014-03-10T15:36:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/705d920e-2018-5190-ad74-0fa739b07a13"", ""word_count"": 378, ""uri"": ""nyt://article/705d920e-2018-5190-ad74-0fa739b07a13""}"
2014-04-06,"{""abstract"": ""Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said."", ""web_url"": ""https://www.nytimes.com/2014/04/07/business/breast-cancer-drug-shows-groundbreaking-results.html"", ""snippet"": ""Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said."", ""lead_paragraph"": ""SAN DIEGO \u2014 Researchers say that a new type of drug can help prevent advanced breast cancer from worsening, potentially providing an important new treatment option for women and a blockbuster product for Pfizer."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Guarded Optimism After Breast Cancer Drug Shows Promising Results"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Guarded Optimism After Breast Cancer Drug Shows Promising Results"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Breast Cancer"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""American Assn for Cancer Research"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Finn, Richard S"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-04-06T14:31:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/54532b87-8972-538a-8d5b-b1599339099b"", ""word_count"": 973, ""uri"": ""nyt://article/54532b87-8972-538a-8d5b-b1599339099b""}"
2014-04-21,"{""abstract"": ""A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/21/spurning-merger-approaches-astrazeneca-pursues-own-path/"", ""snippet"": ""A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry. But whether such a deal makes sense is another matter."", ""lead_paragraph"": ""The British drug company AstraZeneca said no to a tie-up with Pfizer, turning down the possibility of one of the biggest drug mergers in recent history. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/22/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Spurning Merger Approaches, AstraZeneca Pursues Own Path"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Warner-Lambert Co"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-04-21T17:17:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced and Andrew Pollack"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3"", ""word_count"": 976, ""uri"": ""nyt://article/4ce50f9c-f4d3-55e9-ad7b-d1b50b6cd6c3""}"
2014-04-22,"{""abstract"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/22/morning-agenda-ackmans-botox-ambitions/"", ""snippet"": ""William A. Ackman and Valeant are bidding for Allergan, the maker of Botox. | Novartis announced a major overhaul. | AstraZeneca says no to a deal with Pfizer. | Barclays is set to exit its commodities business."", ""lead_paragraph"": ""William A. Ackman, one of the brashest men on Wall Street, has come up with perhaps the boldest move yet for an activist: He has teamed up with the health care company Valeant to bid roughly $50 billion for Allergan, the maker of Botox, David Gelles, Michael J. de la Merced and Alexandra Stevenson write in DealBook. The offer by Valeant is expected to be announced Tuesday morning."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Ackman\u2019s Botox Ambitions"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-22T12:11:47+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2"", ""word_count"": 1946, ""uri"": ""nyt://article/4e027bef-017e-5f33-9c69-f72c49d464c2""}"
2014-04-28,"{""abstract"": ""If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/28/why-pfizer-needs-to-do-more-to-win-astrazeneca/"", ""snippet"": ""If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends."", ""lead_paragraph"": ""Pfizer will need to pile on more pressure if it wants to buy AstraZeneca. Pfizer has confirmed that it made a $99 billion cash-and-stock approach in January for AstraZeneca, its British rival, and is now renewing its suit. AstraZeneca\u2019s chief executive, Pascal Soriot, may ultimately struggle to resist a takeover, but he ought to be able to extract a better proposal."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/29/business/dbpix-astrazeneca-nyse/dbpix-astrazeneca-nyse-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Why Pfizer Needs to Do More to Win AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-04-28T16:36:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303"", ""word_count"": 446, ""uri"": ""nyt://article/eab3f930-477d-5011-8cb8-5e5f305e5303""}"
2014-04-29,"{""abstract"": ""We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column."", ""web_url"": ""https://dealbook.nytimes.com/2014/04/29/how-tax-laws-distort-the-pfizer-deal/"", ""snippet"": ""We don\u2019t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column."", ""lead_paragraph"": ""The United States tax code is fueling Pfizer Inc.\u2019s $98.7 billion bid to take over the London-based pharmaceutical company AstraZeneca. If the deal goes through as proposed, a new parent company in Britain would own the combined entity, making it easier for the new firm to strip income out of its American tax base. The deal is one of several recent transactions known as \u201cinversions,\u201d where a multinational company like Pfizer, based in New York, becomes an expatriate by acquiring a smaller foreign target."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg"", ""height"": 407, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 407}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-jumbo.jpg"", ""height"": 695, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-superJumbo.jpg"", ""height"": 1254, ""width"": 1848, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/04/30/business/dbpix-viagra/dbpix-viagra-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How Tax Laws Distort the Pfizer Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-04-29T19:56:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Victor Fleischer"", ""person"": [{""firstname"": ""Victor"", ""middlename"": null, ""lastname"": ""Fleischer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/521599db-1fca-597c-8642-46e84452abe8"", ""word_count"": 971, ""uri"": ""nyt://article/521599db-1fca-597c-8642-46e84452abe8""}"
2014-05-01,"{""abstract"": ""Time is working against Pfizer in its pursuit of AstraZeneca and thus it will want a friendly deal completed as quickly as possible, Christopher Hughes and Neil Unmack write for Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/01/pfizer-looks-for-a-quick-strike-on-astrazeneca/"", ""snippet"": ""Time is working against Pfizer in its pursuit of AstraZeneca and thus it will want a friendly deal completed as quickly as possible, Christopher Hughes and Neil Unmack write for Reuters Breakingviews."", ""lead_paragraph"": ""Time often benefits bidders rather than targets\u00a0\u2014 that\u2019s why Kraft left its British rival Cadbury flailing for months after making a takeover approach. But the dynamics of Pfizer\u2019s interest in AstraZeneca are unusual. Pfizer has good reason to seek a quick negotiated deal."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/01/business/dealbook/dbpix-pfizer-astra/dbpix-pfizer-tax-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Looks for a Quick Strike on AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-01T19:22:23+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes and Neil Unmack"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/52ca2e11-1743-57fa-855b-982be2cccef9"", ""word_count"": 429, ""uri"": ""nyt://article/52ca2e11-1743-57fa-855b-982be2cccef9""}"
2014-05-02,"{""abstract"": ""Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/02/pfizer-has-yet-to-make-a-compelling-bid-to-astrazenecas-shareholders/"", ""snippet"": ""Pfizer\u2019s latest offer for its rival seems cheap to shareholders who view AstraZeneca\u2019s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer\u2019s courtship of AstraZeneca looks like a hate-hate relationship. In January, the British pharmaceutical firm AstraZeneca viewed its larger rival\u2019s takeover proposal of 46.61 pounds a share as too low on cash, too risky, and too cheap to even talk about. Pfizer\u2019s latest proposal, an effort to get AstraZeneca to begin friendly talks, hasn\u2019t moved the needle much."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg"", ""height"": 444, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 444}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-jumbo.jpg"", ""height"": 758, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-superJumbo.jpg"", ""height"": 1516, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/03/business/dbpix-ian-read/dbpix-ian-read-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Has Yet to Make a Compelling Bid to AstraZeneca\u2019s Shareholders"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-02T17:00:17+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151"", ""word_count"": 403, ""uri"": ""nyt://article/ec8aaf84-5b1a-5c5f-9984-1ea85ce62151""}"
2014-05-05,"{""abstract"": ""Pfizer announced a 15 percent drop in earnings, and again pressed its suit for its rival, AstraZeneca."", ""web_url"": ""https://www.nytimes.com/2014/05/06/business/pfizer-profit-tumbles-15.html"", ""snippet"": ""Pfizer announced a 15 percent drop in earnings, and again pressed its suit for its rival, AstraZeneca."", ""lead_paragraph"": ""As the drug maker Pfizer announced a 15 percent drop in first-quarter earnings on Monday, its chief executive renewed his call for its British rival AstraZeneca to accept Pfizer\u2019s offer to buy it."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-articleLarge.jpg"", ""height"": 835, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/06/business/Pfizer/Pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 835}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 1024, ""width"": 736, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-superJumbo.jpg"", ""height"": 1038, ""width"": 746, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/06/business/Pfizer/Pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Profit Off, Pfizer Again Aims to Lure AstraZeneca"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Profits Off, Pfizer Again Aims to Lure AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Company Reports"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-05T12:57:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/264730d6-adaf-541f-8ab9-019d00864527"", ""word_count"": 592, ""uri"": ""nyt://article/264730d6-adaf-541f-8ab9-019d00864527""}"
2014-05-06,"{""abstract"": ""In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/06/astrazeneca-makes-case-against-pfizers-bid/"", ""snippet"": ""In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer\u2019s bid undervalued the company."", ""lead_paragraph"": ""Updated, 4:39 p.m. | AstraZeneca, the British drug maker, on Tuesday made an impassioned defense for itself as a stand-alone company, just a day after the American pharmaceutical giant Pfizer again pressed its case for a $106 billion takeover offer. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""height"": 440, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 440}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-jumbo.jpg"", ""height"": 751, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-superJumbo.jpg"", ""height"": 1501, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/07/business/dbpix-astrazeneca1/dbpix-astrazeneca1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca Makes Its Case Against Pfizer\u2019s Takeover Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Johansson, Leif"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-05-06T12:02:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson, David Gelles and Stephen Castle"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}, {""firstname"": ""Stephen"", ""middlename"": null, ""lastname"": ""Castle"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 3}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e"", ""word_count"": 1192, ""uri"": ""nyt://article/0c623b11-bdea-5f49-9e0d-774d02f1951e""}"
2014-05-07,"{""abstract"": ""Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/07/a-scientists-defense-of-keeping-astrazeneca-independent/"", ""snippet"": ""Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer."", ""lead_paragraph"": ""Updated, 1:13 p.m. | LONDON \u2014 It is probably no surprise that Briggs Morrison, head of global drug development at AstraZeneca, has sided with his bosses in opposing the idea of the American giant Pfizer taking over the British company."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Scientist\u2019s Defense of Keeping AstraZeneca Independent"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-07T15:42:01+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31"", ""word_count"": 734, ""uri"": ""nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31""}"
2014-05-08,"{""abstract"": ""AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/08/a-case-for-rejecting-pfizers-bid-for-astrazeneca/"", ""snippet"": ""AstraZeneca\u2019s board would do well to evaluate whether the company\u2019s progress will continue under Pfizer\u2019s management, Bill George, a professor at Harvard Business School, writes in the Another View column."", ""lead_paragraph"": ""Bill George is professor of management practice at Harvard Business School, former chairman and chief executive of Medtronic and author of \u201cTrue North,\u201d a book about authentic leadership. He serves on the boards of ExxonMobil, Goldman Sachs and the Mayo Clinic. In the past two years, he has taught custom leadership programs at Harvard for AstraZeneca executives and consulted with the company in 2012-13. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/dbpix-pfizer1/dbpix-pfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Case for Rejecting Pfizer\u2019s Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soriot, Pascal"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-08T19:35:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Bill George"", ""person"": [{""firstname"": ""Bill"", ""middlename"": null, ""lastname"": ""George"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170"", ""word_count"": 906, ""uri"": ""nyt://article/9d49b9ad-e7d8-5273-9522-c2705691b170""}"
2014-05-09,"{""abstract"": ""Walgreen is already under pressure from hedge fund investors that want it to move across the Atlantic."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/08/pfizer-plan-to-go-to-london-spurs-other-companies-to-consider-moving-abroad/"", ""snippet"": ""Walgreen is already under pressure from hedge fund investors that want it to move across the Atlantic."", ""lead_paragraph"": ""Pfizer\u2019s attempt to escape the United States corporate tax rate by acquiring a British drug maker has set off a flurry of activity in other big companies across the country, at investment banks on Wall Street and in offices on Capitol Hill."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/09/business/Mergers/Mergers-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/09/business/Mergers/Mergers-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/09/business/Mergers/Mergers-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Plan to Go to London Spurs Other Companies to Consider Moving Abroad"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer\u2019s Plan to Go to London Spurs Other Companies to Consider Moving Abroad"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Buffett, Warren E"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Carl M"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Walgreen Company"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-09T00:33:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e0878883-cd0f-556f-bfec-a48be6cf7671"", ""word_count"": 977, ""uri"": ""nyt://article/e0878883-cd0f-556f-bfec-a48be6cf7671""}"
2014-05-10,"{""abstract"": ""In a series of videos posted online, Pfizer\u2019s chief executive tried to quell growing concern about the transaction."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/10/pfizer-continues-to-defend-takeover-bid-for-astrazeneca/"", ""snippet"": ""In a series of videos posted online, Pfizer\u2019s chief executive tried to quell growing concern about the transaction."", ""lead_paragraph"": ""Pfizer on Saturday continued to press its case for a $106 billion takeover of AstraZeneca, the British drug maker, in the face of mounting resistance on both sides of the Atlantic. "", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-articleLarge.jpg"", ""height"": 338, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 338}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-jumbo.jpg"", ""height"": 577, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-superJumbo.jpg"", ""height"": 620, ""width"": 1100, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/11/business/dbpix-pfizer/dbpix-pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Continues to Defend Takeover Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-10T17:41:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c2188814-8b16-5e82-9e94-1f6c4c063992"", ""word_count"": 509, ""uri"": ""nyt://article/c2188814-8b16-5e82-9e94-1f6c4c063992""}"
2014-05-12,"{""abstract"": ""BNP Paribas and Credit Suisse ask authorities in the United States to go easy. | Pfizer goes online to defend its bid for AstraZeneca. | Timothy F. Geithner\u2019s book, \u201cStress Test,\u201d comes out today. | Morgan Stanley is king in Silicon Valley."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/12/morning-agenda-2-banking-giants-ask-for-leniency/"", ""snippet"": ""BNP Paribas and Credit Suisse ask authorities in the United States to go easy. | Pfizer goes online to defend its bid for AstraZeneca. | Timothy F. Geithner\u2019s book, \u201cStress Test,\u201d comes out today. | Morgan Stanley is king in Silicon Valley."", ""lead_paragraph"": ""Facing the threat of criminal charges, BNP Paribas and Credit Suisse are imploring authorities in the United States for leniency, Ben Protess and Jessica Silver-Greenberg write in DealBook. To avoid fallout from pleading guilty, the banks are said to have made last-ditch appeals to prosecutors and regulators in recent weeks."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""BNP Paribas and Credit Suisse Seek Leniency"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-05-12T11:41:22+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c8028602-229a-53ca-a22b-f5aa54ebb5b6"", ""word_count"": 1839, ""uri"": ""nyt://article/c8028602-229a-53ca-a22b-f5aa54ebb5b6""}"
2014-05-13,"{""abstract"": ""One lesson for companies contemplating a big merger, Steven M. Davidoff writes in the Deal Professor column: Life is not a \u201cMad Men\u201d episode where ego and hubris triumph."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/13/lessons-from-the-breakup-of-an-advertising-merger/"", ""snippet"": ""One lesson for companies contemplating a big merger, Steven M. Davidoff writes in the Deal Professor column: Life is not a \u201cMad Men\u201d episode where ego and hubris triumph."", ""lead_paragraph"": ""\u201cOh, never mind.\u201d"", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-jumbo.jpg"", ""height"": 1024, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-superJumbo.jpg"", ""height"": 1190, ""width"": 1190, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/14/business/dbpix-dealprof/dbpix-dealprof-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""To Guide the Merger Giants, Strong Hands Are Needed"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""To Guide the Merger Giants, Strong Hands Are Needed"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levy, Maurice"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Sorrell, Martin"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Wren, John D"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Omnicom Group Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Publicis Groupe"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-05-13T20:30:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a908a4f7-d0a5-570b-be71-8c30b993165a"", ""word_count"": 1144, ""uri"": ""nyt://article/a908a4f7-d0a5-570b-be71-8c30b993165a""}"
2014-05-15,"{""abstract"": ""A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/15/the-right-price-for-astrazenecas-stock/"", ""snippet"": ""A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen."", ""lead_paragraph"": ""Investors are putting a lot of faith in Pfizer succeeding in its $100 billion-plus quest to acquire British pharmaceuticals rival AstraZeneca. The right price for the target\u2019s share price can be seen as the weighted average of two possible outcomes \u2013 a sale to Pfizer or a standalone future. A new Breakingviews calculator shows why the market seems to think a transaction will probably happen."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/17/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Right Price for AstraZeneca\u2019s Stock"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-15T18:54:48+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149"", ""word_count"": 360, ""uri"": ""nyt://article/d87bc7ef-a7d0-577b-869b-6b268df07149""}"
2014-05-18,"{""abstract"": ""The American drug giant Pfizer has made an offer worth $119 billion in what it said was a final effort to bring the British drug maker AstraZeneca to the table for deal talks."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/18/pfizer-raises-bid-for-astrazeneca/"", ""snippet"": ""The American drug giant Pfizer has made an offer worth $119 billion in what it said was a final effort to bring the British drug maker AstraZeneca to the table for deal talks."", ""lead_paragraph"": ""Pfizer has again raised its offer for AstraZeneca, making what it said was a final effort to bring the giant British drug maker to the negotiating table."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-articleLarge.jpg"", ""height"": 441, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/19/business/drug/drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 441}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-jumbo.jpg"", ""height"": 752, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-superJumbo.jpg"", ""height"": 1255, ""width"": 1709, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/19/business/drug/drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/19/business/drug/drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""In Last-Ditch Bid, Pfizer Offers $119 Billion for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""In Last-Ditch Bid, Pfizer Offers $119 Billion for AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Levin, Carl M"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-18T21:19:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e9310a1-1019-5221-9d44-12265822d3ee"", ""word_count"": 848, ""uri"": ""nyt://article/3e9310a1-1019-5221-9d44-12265822d3ee""}"
2014-05-19,"{""abstract"": ""Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/19/the-curious-incident-of-pfizers-final-offer-for-astrazeneca/"", ""snippet"": ""Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column."", ""lead_paragraph"": ""In its bid for AstraZeneca, Pfizer is finding out that some merger offers need to be sweet enough for everyone."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-jumbo.jpg"", ""height"": 970, ""width"": 970, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-superJumbo.jpg"", ""height"": 970, ""width"": 970, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-dealprof/dbpix-dealprof-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Curious Incident of Pfizer\u2019s \u2018Final\u2019 Offer for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-05-19T16:09:20+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975"", ""word_count"": 884, ""uri"": ""nyt://article/1a3cf152-03f0-5760-95f1-ff900aae6975""}"
2014-05-20,"{""abstract"": ""An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/20/loophole-offers-pfizer-a-risky-way-back-into-a-deal/"", ""snippet"": ""An apparent loophole in Britain\u2019s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was \u201cfinal,\u201d says Christopher Hughes of Reuters Breakingviews."", ""lead_paragraph"": ""Pfizer has a risky way back into a deal with AstraZeneca. An apparent loophole in Britain\u2019s takeover code means that the American pharmaceutical giant could offer the 58.85 pounds-a-share demanded by Astra for a recommendation, even after declaring that the earlier \u00a355-a-share pitch was \u201cfinal.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Loophole Offers Pfizer a Risky Way Back Into a Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-05-20T17:29:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd"", ""word_count"": 339, ""uri"": ""nyt://article/c88d558c-9fc7-54c8-8fac-f4ce5d8dc5bd""}"
2014-05-21,"{""abstract"": ""The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/21/astrazenecas-shareholders-remain-sharply-divided-over-talks-with-pfizer/"", ""snippet"": ""The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid."", ""lead_paragraph"": ""LONDON \u2013 AstraZeneca\u2019s decision not to pursue merger talks with Pfizer\u00a0 has caused a split among the British-Swedish drug maker\u2019s shareholders, \u00a0with several large shareholders publicly and privately voicing opposing views on Wednesday on the potential tie-up."", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca\u2019s Shareholders Remain Sharply Divided Over Talks With Pfizer"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Shareholders Divided"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Axa SA"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-21T17:42:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1"", ""word_count"": 607, ""uri"": ""nyt://article/4e0d2234-1084-5b9f-bc10-6e74820978f1""}"
2014-05-22,"{""abstract"": ""BlackRock, AstraZeneca\u2019s largest shareholder, is said to prefer that the drug firm engage in talks with Pfizer later on rather than accept Pfizer\u2019s most recent offer."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/22/blackrock-encourages-astrazeneca-to-renew-pfizer-talks-at-later-date/"", ""snippet"": ""BlackRock, AstraZeneca\u2019s largest shareholder, is said to prefer that the drug firm engage in talks with Pfizer later on rather than accept Pfizer\u2019s most recent offer."", ""lead_paragraph"": ""LONDON \u2013 AstraZeneca\u2019s largest shareholder, BlackRock, wants the drugmaker to renew its talks with Pfizer about a potential deal at a later date, according to a person familiar with the discussions."", ""print_section"": ""B"", ""print_page"": ""7"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/22/business/dbpix-drug1/dbpix-drug1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""BlackRock Encourages AstraZeneca to Renew Pfizer Talks at Later Date"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Early Retirement"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BlackRock Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-22T16:55:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4b7bfb0e-2516-5e1f-8a67-068b09a7e309"", ""word_count"": 450, ""uri"": ""nyt://article/4b7bfb0e-2516-5e1f-8a67-068b09a7e309""}"
2014-05-26,"{""abstract"": ""Pfizer said it \u201cdoes not intend to make an offer for AstraZeneca\u201d in the wake of AstraZeneca\u2019s rejection of a $119 billion bid."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/26/pfizers-says-its-bid-for-astrazeneca-is-dead/"", ""snippet"": ""Pfizer said it \u201cdoes not intend to make an offer for AstraZeneca\u201d in the wake of AstraZeneca\u2019s rejection of a $119 billion bid."", ""lead_paragraph"": ""Updated, 9:36 p.m. | On the final day for Pfizer to decide whether to abandon the plan, it said it did not intend to make an offer for AstraZeneca. Last week, the British company rejected what Pfizer had called its final offer. The cash-and-stock bid, which valued AstraZeneca at about $119 billion, would have created the world\u2019s largest drug company."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-articleLarge.jpg"", ""height"": 366, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 366}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-jumbo.jpg"", ""height"": 625, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-superJumbo.jpg"", ""height"": 1250, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/26/business/26dbpix-astrazeneca/26dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Abandons Bid for AstraZeneca"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Pfizer Abandons Bid for AstraZeneca"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-26T14:39:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Jenny Anderson"", ""person"": [{""firstname"": ""Jenny"", ""middlename"": null, ""lastname"": ""Anderson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/73fdd200-9ca2-5913-be04-69d619de876a"", ""word_count"": 630, ""uri"": ""nyt://article/73fdd200-9ca2-5913-be04-69d619de876a""}"
2014-05-27,"{""abstract"": ""Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/05/27/the-lessons-of-a-failed-drug-deal/"", ""snippet"": ""Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes."", ""lead_paragraph"": ""The failure of Pfizer\u2019s $119 billion bid for AstraZeneca leaves the frustrated buyer no worse off. But AstraZeneca has much to prove. Some of its shareholders welcomed a possible takeover \u2013 and could again."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""height"": 900, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 900}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-jumbo.jpg"", ""height"": 1024, ""width"": 683, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-superJumbo.jpg"", ""height"": 2048, ""width"": 1366, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/05/20/business/dbpix-drug-breakingviews1/dbpix-drug-breakingviews1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Lessons of a Drug Maker\u2019s Failed Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-05-27T15:49:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Christopher Hughes"", ""person"": [{""firstname"": ""Christopher"", ""middlename"": null, ""lastname"": ""Hughes"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff"", ""word_count"": 343, ""uri"": ""nyt://article/673a4161-a3dd-5c7c-b644-091be9e918ff""}"
2014-05-29,"{""abstract"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""web_url"": ""https://www.nytimes.com/2014/05/30/business/international/italy-seeks-1-6-billion-in-damages-from-roche-and-novartis.html"", ""snippet"": ""The government says the national health service suffered losses from the drug companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""lead_paragraph"": ""PARIS \u2014 The Italian government is seeking $1.6 billion in damages from two of the world\u2019s biggest drug companies \u2014 Novartis and Roche \u2014 for losses that it says the national health service incurred from the companies\u2019 efforts to restrict competition in ophthalmic drugs."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Italy Seeks $1.6 Billion in Damages From Roche and Novartis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Novartis and Roche Face Fines in Italy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Jolly, David"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pianigiani, Gaia"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Italy"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-05-29T16:26:04+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By David Jolly and Gaia Pianigiani"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Jolly"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Gaia"", ""middlename"": null, ""lastname"": ""Pianigiani"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8"", ""word_count"": 449, ""uri"": ""nyt://article/99050c46-617e-5a06-9a52-08fd3ecde0c8""}"
2014-06-16,"{""abstract"": ""Bill George, a former chief executive of Medtronic, opposed Pfizer\u2019s proposed deal to acquire an overseas competitor and reincorporate abroad, but he is all in favor of his former employer making a similar deal."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/16/former-medtronic-c-e-o-defends-inversion-deal/"", ""snippet"": ""Bill George, a former chief executive of Medtronic, opposed Pfizer\u2019s proposed deal to acquire an overseas competitor and reincorporate abroad, but he is all in favor of his former employer making a similar deal."", ""lead_paragraph"": ""Bill George, a former chief executive of the medical device maker Medtronic, came out last month against Pfizer\u2019s proposed inversion \u2013 a deal to acquire an overseas competitor and reincorporate abroad, lowering tax rates and freeing up overseas cash."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/17/business/dbpix-george/dbpix-george-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-superJumbo.jpg"", ""height"": 1367, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/17/business/dbpix-george/dbpix-george-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Former Medtronic C.E.O. Defends Inversion Deal"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""George, William W"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Ireland"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-06-16T16:13:27+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b4212ed8-0a2e-507e-8049-3d8fc41fd2e3"", ""word_count"": 483, ""uri"": ""nyt://article/b4212ed8-0a2e-507e-8049-3d8fc41fd2e3""}"
2014-06-24,"{""abstract"": ""Two BNP Paribas analysts said in a research note that a sweetened offer of about $127.7 billion by Pfizer for its British rival would still make \u201ceconomic sense.\u201d"", ""web_url"": ""https://dealbook.nytimes.com/2014/06/24/bank-analysts-say-pfizer-astrazeneca-merger-still-makes-sense/"", ""snippet"": ""Two BNP Paribas analysts said in a research note that a sweetened offer of about $127.7 billion by Pfizer for its British rival would still make \u201ceconomic sense.\u201d"", ""lead_paragraph"": ""LONDON \u2014 Analysts at BNP Paribas think a potential merger between AstraZeneca and Pfizer may not be dead despite AstraZeneca\u2019s repeated rejections of a deal between the drug makers."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/25/business/dbpix-pfizer1/dbpix-pfizer1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Bank Analysts Say Pfizer-AstraZeneca Merger Still Makes Sense"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BNP Paribas"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-06-24T11:37:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/114d6261-f048-5372-8f79-d548f29de11a"", ""word_count"": 286, ""uri"": ""nyt://article/114d6261-f048-5372-8f79-d548f29de11a""}"
2014-06-25,"{""abstract"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/25/abbvie-signals-it-will-continue-to-pursue-irish-drug-maker-shire/"", ""snippet"": ""Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire."", ""lead_paragraph"": ""Updated, 2:28 p.m. | "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/06/26/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie Signals It Will Continue to Pursue Irish Drug Maker Shire"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Defending Its Offer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gonzalez, Richard"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-06-25T13:06:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab"", ""word_count"": 804, ""uri"": ""nyt://article/6f8402b9-2f2e-55f8-9167-a229e3f030ab""}"
2014-06-26,"{""abstract"": ""Auxilium Pharmaceuticals, based in Pennsylvania, agreed to acquire QLT of Canada in one of the smallest inversions in recent years."", ""web_url"": ""https://dealbook.nytimes.com/2014/06/26/auxilium-buys-qlt-as-a-small-player-does-an-inversion-too/"", ""snippet"": ""Auxilium Pharmaceuticals, based in Pennsylvania, agreed to acquire QLT of Canada in one of the smallest inversions in recent years."", ""lead_paragraph"": ""Most of the corporate inversions that have grabbed headlines recently have been attempted by multibillion-dollar stalwarts of United States industry like Pfizer, Chiquita and Medtronic. But smaller companies can benefit from striking deals to move abroad, too. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Auxilium, a Small Player, Buys QLT and Does an Inversion, Too"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2014-06-26T16:23:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/068e3bf7-cc07-5b21-80ae-8362769e458e"", ""word_count"": 357, ""uri"": ""nyt://article/068e3bf7-cc07-5b21-80ae-8362769e458e""}"
2014-07-02,"{""abstract"": ""As more companies seek to relocate by mergers \u2014 so-called inversions \u2014 it is more likely the law will change, Robert Cyran of Reuters Breakingviews writes."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/02/the-fleeting-benefits-of-overseas-corporate-marriages/"", ""snippet"": ""As more companies seek to relocate by mergers \u2014 so-called inversions \u2014 it is more likely the law will change, Robert Cyran of Reuters Breakingviews writes."", ""lead_paragraph"": ""Tax-arbitrage mergers and acquisitions require a deep discount. American companies seeking to relocate by mergers in a bid to slash how much they pay Uncle Sam were a big part of the $1.8 trillion first-half deal boom. The benefits of such ill-conceived combinations will be fleeting, though. The more so-called inversions there are, the more likely the law is to change."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-articleLarge.jpg"", ""height"": 246, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 246}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-jumbo.jpg"", ""height"": 420, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-superJumbo.jpg"", ""height"": 839, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/03/business/dbpix-medtronic/dbpix-medtronic-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Fleeting Benefits of Overseas Corporate Marriages"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-07-02T17:01:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/76cd9ae5-b1b5-57dd-b0ba-d7bf9fbbb4e7"", ""word_count"": 384, ""uri"": ""nyt://article/76cd9ae5-b1b5-57dd-b0ba-d7bf9fbbb4e7""}"
2014-07-14,"{""abstract"": ""Vince Cable, the British business secretary, wants to eliminate the \u201cwiggle room\u201d in commitments made by foreign suitors for British companies."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/14/government-official-calls-for-stricter-takeover-rules-in-britain/"", ""snippet"": ""Vince Cable, the British business secretary, wants to eliminate the \u201cwiggle room\u201d in commitments made by foreign suitors for British companies."", ""lead_paragraph"": ""LONDON \u2013 Vince Cable, the British business secretary, is calling for stricter rules to regulate acquisitions of British companies by overseas competitors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-articleLarge.jpg"", ""height"": 463, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 463}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-jumbo.jpg"", ""height"": 791, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-superJumbo.jpg"", ""height"": 1582, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/15/business/dbpix-vince-cable/dbpix-vince-cable-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Call for Stricter Takeover Rules in Britain"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Cable, Vince"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-07-14T10:45:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9c36040f-86c8-5232-acc2-ecf880071553"", ""word_count"": 364, ""uri"": ""nyt://article/9c36040f-86c8-5232-acc2-ecf880071553""}"
2014-07-15,"{""abstract"": ""The pharmaceutical company is hoping to bring a new acronym into the vernacular with FOGO, or fear of getting old."", ""web_url"": ""https://www.nytimes.com/2014/07/16/business/media/pfizer-to-inject-youth-into-the-aging-process.html"", ""snippet"": ""The pharmaceutical company is hoping to bring a new acronym into the vernacular with FOGO, or fear of getting old."", ""lead_paragraph"": ""Acronyms seem to be growing more prevalent in the vernacular, among them BOGO, for buy one, get one; YOLO, you only live once; and FOMO, fear of missing out. To that list, the pharmaceutical giant Pfizer hopes to add FOGO, a.k.a. fear of getting old."", ""print_section"": ""B"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/16/business/Adco/Adco-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-superJumbo.jpg"", ""height"": 1234, ""width"": 1851, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/16/business/Adco/Adco-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/16/business/Adco/Adco-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer to Inject Youth Into the Aging Process"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer to Inject Youth Into the Aging Process"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Elliott, Stuart"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Elderly"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""ADVERTISING AND MARKETING"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-07-15T23:56:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""Media"", ""byline"": {""original"": ""By Stuart Elliott"", ""person"": [{""firstname"": ""Stuart"", ""middlename"": null, ""lastname"": ""Elliott"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/86c5472e-483f-5fd4-9442-b44f707523c4"", ""word_count"": 890, ""uri"": ""nyt://article/86c5472e-483f-5fd4-9442-b44f707523c4""}"
2014-07-24,"{""abstract"": ""Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/24/allergans-bosses-put-money-on-where-their-mouths-are/"", ""snippet"": ""Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals. It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews."", ""lead_paragraph"": ""Allergan\u2018s bosses have put money where their mouths are."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg"", ""height"": 444, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 444}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-jumbo.jpg"", ""height"": 757, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-superJumbo.jpg"", ""height"": 1036, ""width"": 1401, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/dbpix-allergan1/dbpix-allergan1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Botox Maker\u2019s Bosses Put Money Where Their Mouths Are"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Executive Compensation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-07-24T16:04:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532"", ""word_count"": 385, ""uri"": ""nyt://article/7c1279c1-aa77-511a-8b4f-49a8ae1e1532""}"
2014-07-25,"{""abstract"": ""How AbbVie came to win Shire demonstrates that even in the middle of a new boom in mergers and acquisitions, a hefty premium is no guarantee of success."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/24/to-woo-shire-abbvie-trod-cautiously-in-takeover-bid/"", ""snippet"": ""How AbbVie came to win Shire demonstrates that even in the middle of a new boom in mergers and acquisitions, a hefty premium is no guarantee of success."", ""lead_paragraph"": ""Susan Kilsby had not been chairwoman of the drug maker Shire for even a week when she received an office call that would set off a frenzied trans-Atlantic courtship."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-articleLarge.jpg"", ""height"": 394, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/25/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 394}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-jumbo.jpg"", ""height"": 673, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-superJumbo.jpg"", ""height"": 1345, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/25/business/Drug/Drug-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/25/business/Drug/Drug-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""To Woo Drug Maker Shire, AbbVie Trod Cautiously in Tax Inversion Bid"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""To Woo Shire, AbbVie Trod Cautiously in Takeover Bid"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Abbott Laboratories"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-07-25T00:31:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cbf63f2d-f877-5c94-9bd6-9fd139d09c84"", ""word_count"": 1129, ""uri"": ""nyt://article/cbf63f2d-f877-5c94-9bd6-9fd139d09c84""}"
2014-07-30,"{""abstract"": ""The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met."", ""web_url"": ""https://dealbook.nytimes.com/2014/07/30/astrazeneca-to-pay-up-to-2-1-billion-for-respiratory-drugs/"", ""snippet"": ""The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met."", ""lead_paragraph"": ""Updated, 9:30 a.m. | LONDON \u2013 AstraZeneca of Britain said on Wednesday that it had agreed to pay up to $2.1 billion for a slate of respiratory drugs from the Spanish drug maker Almirall."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/07/31/business/dbpix-astrazeneca/dbpix-astrazeneca-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca to Pay Almirall Up to $2.1 Billion for Respiratory Drugs"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Chronic Obstructive Pulmonary Disease"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Respiratory Diseases"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Almirall SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxter International"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2014-07-30T09:20:13+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6"", ""word_count"": 356, ""uri"": ""nyt://article/3500a053-4cec-5aee-b1d3-88db49252df6""}"
2014-09-02,"{""abstract"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/01/public-pension-funds-stay-mum-on-corporate-expats/"", ""snippet"": ""Public pension funds have major stakes in American companies moving overseas to cut their tax bills. But they are saying little about the strategy, which could hurt the nation\u2019s tax base."", ""lead_paragraph"": ""In the outcry about the recent merger mania to take advantage of the tax avoidance transactions known as inversions, certain key players have been notably silent: public pension funds."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/01/business/dealbook/dbpix-simpson/dbpix-simpson-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Public Pension Funds Stay Mum on Corporate Expats"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Staying Mum on Corporate Expats"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Pensions and Retirement Plans"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Burger King Corp"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tim Hortons"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-02T01:05:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee"", ""word_count"": 1192, ""uri"": ""nyt://article/aeace868-deae-52b3-84a2-f22a8cfd25ee""}"
2014-09-23,"{""abstract"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""web_url"": ""https://dealbook.nytimes.com/2014/09/23/u-s-curbs-on-inversions-may-deter-some-pharmaceutical-deals/"", ""snippet"": ""Some American-led transactions may survive on strategic logic. But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write."", ""lead_paragraph"": ""The clampdown by the United States on tax-driven cross-border mergers and acquisitions should deter half-baked pharmaceutical deals. Some American-led transactions, like AbbVie\u2019s recent agreement to buy its British rival Shire, may survive on strategic logic. But pure tax-avoiding combinations look tricky."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""height"": 382, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 382}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-jumbo.jpg"", ""height"": 653, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-superJumbo.jpg"", ""height"": 1305, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/09/24/business/dbpix-shire/dbpix-shire-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Curbs on Inversions May Deter Some Pharmaceutical Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2014-09-23T19:16:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack and Robert Cyran"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e"", ""word_count"": 383, ""uri"": ""nyt://article/969361d7-4dca-50d8-863c-77f15acebf4e""}"
2014-10-04,"{""abstract"": ""Companies like Allergan, Valeant, Salix, Actavis and Medtronic are riding a wave of cheap debt and pent-up demand in a slew of recent acquisitions or attempted acquisitions."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/03/a-scramble-to-acquire-for-drug-companies/"", ""snippet"": ""Companies like Allergan, Valeant, Salix, Actavis and Medtronic are riding a wave of cheap debt and pent-up demand in a slew of recent acquisitions or attempted acquisitions."", ""lead_paragraph"": ""A chain reaction of deal-making and acquisition talks is continuing to reshape the pharmaceutical industry, with a handful of big companies jostling to outmaneuver their competitors."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-articleLarge-v2.jpg"", ""height"": 399, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/04/business/04drug-jp/04drug-jp-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 399}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-jumbo-v2.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-superJumbo-v2.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/04/business/04drug-jp/04drug-jp-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Scramble to Acquire for Drug Companies"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""A Scramble to Acquire for Drug Companies"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Covidien plc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Salix Pharmaceuticals Ltd"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-10-04T01:23:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/04e4e168-9d4b-5331-93ea-3d30f5dda513"", ""word_count"": 845, ""uri"": ""nyt://article/04e4e168-9d4b-5331-93ea-3d30f5dda513""}"
2014-10-14,"{""abstract"": ""Already, 2014 ranks as the busiest year for failed mergers since 2008, data from Thomson Reuters shows."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/14/an-ill-fated-bid-for-t-mobile-is-the-latest-in-a-year-of-failed-deals/"", ""snippet"": ""Already, 2014 ranks as the busiest year for failed mergers since 2008, data from Thomson Reuters shows."", ""lead_paragraph"": ""Bankers who advise on mergers and acquisitions have had plenty of assignments this year. It\u2019s just that a large portion of their advice is being spent on deals that fail to materialize."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-articleLarge.jpg"", ""height"": 385, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 385}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-jumbo.jpg"", ""height"": 658, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-superJumbo.jpg"", ""height"": 1315, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/14/business/dbpix-mobile2/dbpix-mobile2-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""An Ill-Fated Bid for T-Mobile US is the Latest in a Year of Failed Deals"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Telephones and Telecommunications"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Wireless Communications"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Iliad SA"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""T-Mobile US Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Thomson Reuters Corporation"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2014-10-14T15:56:42+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By William Alden"", ""person"": [{""firstname"": ""William"", ""middlename"": null, ""lastname"": ""Alden"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/bbcbf985-3738-59dc-8717-5f434754cd6b"", ""word_count"": 335, ""uri"": ""nyt://article/bbcbf985-3738-59dc-8717-5f434754cd6b""}"
2014-10-15,"{""abstract"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""web_url"": ""https://dealbook.nytimes.com/2014/10/15/abbvies-u-turn-shows-shire-deal-was-driven-by-taxes/"", ""snippet"": ""The American drug company\u2019s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future."", ""lead_paragraph"": ""AbbVie\u2019s U-turn shows its Shire deal was mostly about tax breaks, after all."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""height"": 360, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 360}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-jumbo.jpg"", ""height"": 614, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-superJumbo.jpg"", ""height"": 1200, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/10/16/business/dbpix-abbvie-tablets/dbpix-abbvie-tablets-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AbbVie\u2019s U-Turn Shows Shire Deal Was Driven by Taxes"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AbbVie Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Shire PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-10-15T15:59:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Neil Unmack"", ""person"": [{""firstname"": ""Neil"", ""middlename"": null, ""lastname"": ""Unmack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520"", ""word_count"": 378, ""uri"": ""nyt://article/c1e1c3fc-3338-5e8f-a5dc-ca3ab37a8520""}"
2014-10-29,"{""abstract"": ""The strain, known as serogroup B meningitis, infected students at Princeton and the University of California, Santa Barbara last year."", ""web_url"": ""https://www.nytimes.com/2014/10/30/business/fda-approves-vaccine-for-rare-meningitis.html"", ""snippet"": ""The strain, known as serogroup B meningitis, infected students at Princeton and the University of California, Santa Barbara last year."", ""lead_paragraph"": ""The Food and Drug Administration said on Wednesday that it had approved a vaccine for a dangerous strain of meningitis that caused outbreaks last year at Princeton and the University of California, Santa Barbara."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""F.D.A. Approves Pfizer\u2019s Trumenba, a Vaccine for a Rare Meningitis"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""F.D.A. Approves Vaccine for Rare Meningitis"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Meningitis"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Vaccination and Immunization"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2014-10-29T22:34:00+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/307873ee-28e7-5ff8-8574-c85c23d4d8d6"", ""word_count"": 464, ""uri"": ""nyt://article/307873ee-28e7-5ff8-8574-c85c23d4d8d6""}"
2014-11-11,"{""abstract"": ""The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/11/zoetis-an-animal-health-company-says-ackman-has-taken-a-stake/"", ""snippet"": ""The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer."", ""lead_paragraph"": ""The activist investor William A. Ackman appears to have found yet another target for his hedge fund in the health care industry: Zoetis, the former animal health arm of Pfizer that is now a $21.8 billion publicly traded company."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-articleLarge.png"", ""height"": 720, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-articleLarge.png"", ""xlargewidth"": 600, ""xlargeheight"": 720}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-jumbo.png"", ""height"": 1024, ""width"": 854, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-superJumbo.png"", ""height"": 1249, ""width"": 1041, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbStandard.png"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbStandard.png"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/12/business/dbpix-zoetis3/dbpix-zoetis3-thumbLarge.png"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Zoetis, an Animal Health Company, Says Ackman Has Taken a Stake"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sachem Head Capital Management"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2014-11-11T22:28:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/2244ab10-52dc-57ee-9e96-0c68f182a801"", ""word_count"": 307, ""uri"": ""nyt://article/2244ab10-52dc-57ee-9e96-0c68f182a801""}"
2014-11-13,"{""abstract"": ""Groups including the Bill & Melinda Gates Foundation aim to help bring an easier-to-inject form of Depo-Provera to 69 countries."", ""web_url"": ""https://www.nytimes.com/2014/11/14/business/pfizer-and-aid-groups-team-up-on-depo-provera-for-developing-world.html"", ""snippet"": ""Groups including the Bill & Melinda Gates Foundation aim to help bring an easier-to-inject form of Depo-Provera to 69 countries."", ""lead_paragraph"": ""Depo-Provera, an injectable contraceptive given once every three months, is already a popular choice of women in developing countries, who value the convenience and discretion of not having to take a daily birth control pill."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-articleLarge.jpg"", ""height"": 403, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/11/14/business/Pfizer/Pfizer-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 403}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-jumbo.jpg"", ""height"": 688, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-superJumbo.jpg"", ""height"": 1376, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/11/14/business/Pfizer/Pfizer-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Aid Groups Team Up on Contraceptive for Developing World"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer and Aid Groups Team Up on Contraceptive for Developing World"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Thomas, Katie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Birth Control and Family Planning"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Third World and Developing Countries"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Gates, Bill and Melinda, Foundation"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2014-11-13T15:01:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Katie Thomas"", ""person"": [{""firstname"": ""Katie"", ""middlename"": null, ""lastname"": ""Thomas"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/730b9e57-68da-5ff9-b895-136d23058aee"", ""word_count"": 600, ""uri"": ""nyt://article/730b9e57-68da-5ff9-b895-136d23058aee""}"
2014-11-17,"{""abstract"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""web_url"": ""https://dealbook.nytimes.com/2014/11/17/pfizer-to-pay-up-to-2-9-billion-in-cancer-drug-deal-with-merck-of-germany/"", ""snippet"": ""The alliance between the American and German companies is expected to strengthen Merck\u2019s oncology business in several important markets, including the United States."", ""lead_paragraph"": ""LONDON \u2014 Merck of Germany said on Monday that the American drug giant Pfizer had agreed to pay $850 million upfront and as much as $2 billion later in a deal to jointly develop one of Merck\u2019s cancer drugs."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer to Pay up to $2.9 Billion in Cancer Drug Deal With Merck of Germany"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Medicine and Health"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck of Germany"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""United States"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2014-11-17T10:32:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132"", ""word_count"": 415, ""uri"": ""nyt://article/33223746-b95c-55ec-8365-355da0986132""}"
2014-12-08,"{""abstract"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""web_url"": ""https://dealbook.nytimes.com/2014/12/08/merck-agrees-to-acquire-drug-maker-cubist-for-9-5-billion/"", ""snippet"": ""The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals."", ""lead_paragraph"": ""Deal making in the health care industry has been booming all year, with medical technology companies and cosmetic drug makers changing hands at rich premiums."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2014/12/09/business/Drug/Drug-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2014/12/09/business/Drug/Drug-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2014/12/09/business/Drug/Drug-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Merck in $8.4 Billion Deal for Cubist, Big Maker of Antibiotics"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""Merck in Deal for Big Maker of Antibiotics"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Biotechnology and Bioengineering"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Cubist Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2014-12-08T12:53:59+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By David Gelles"", ""person"": [{""firstname"": ""David"", ""middlename"": null, ""lastname"": ""Gelles"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698"", ""word_count"": 970, ""uri"": ""nyt://article/d7ab937e-c988-5d8e-a3ba-2a9d72be2698""}"
2015-01-09,"{""abstract"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""web_url"": ""https://www.nytimes.com/2015/01/10/business/ear-disorders-long-neglected-attract-drug-makers-attention-.html"", ""snippet"": ""In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus."", ""lead_paragraph"": ""Driving to a meeting in 2008, Jay Lichter, a venture capitalist, suddenly became so dizzy he had to pull over and call a friend to take him to the emergency room."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""height"": 411, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/01/10/business/10ear-web1/10ear-web1-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 411}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-jumbo-v2.jpg"", ""height"": 702, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-superJumbo-v2.jpg"", ""height"": 1405, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/01/10/business/10ear-web1/10ear-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""From Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs  "", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Music to the Ears"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Ears and Hearing"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Otonomy Inc."", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Auris Medical Holding A.G."", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novartis AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Start-ups"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tinnitus"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Avalon Ventures Limited"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-01-09T20:31:58+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0"", ""word_count"": 1501, ""uri"": ""nyt://article/77297f1a-2dbd-57a9-a2e9-8e4a55b021e0""}"
2015-02-05,"{""abstract"": ""In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/05/pfizer-deal-and-other-mergers-show-a-case-of-the-mondays-on-a-thursday/"", ""snippet"": ""In what might be called \u201ctransaction Thursday,\u201d some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer\u2019s purchase of Hospira and BT\u2019s acquisition of the mobile carrier EE."", ""lead_paragraph"": ""Wall Street has a late-in-the-week case of the Mondays."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg"", ""height"": 435, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 435}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-jumbo.jpg"", ""height"": 743, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-superJumbo.jpg"", ""height"": 1486, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/02/06/business/dbpix-drug-thursday1/dbpix-drug-thursday1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Deal and Other Mergers Show a Case of the Mondays, on a Thursday"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Ball Corporation"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BT Group PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""EE Ltd"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hospira Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-02-05T19:12:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By William Alden"", ""person"": [{""firstname"": ""William"", ""middlename"": null, ""lastname"": ""Alden"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98"", ""word_count"": 351, ""uri"": ""nyt://article/4169eb8b-d302-52f9-b45d-4cb565c28e98""}"
2015-02-06,"{""abstract"": ""RadioShack files for bankruptcy. | Ally Financial is looking to ramp up performance. | Pfizer makes a big bet on a new class of generics. | Dysfunction continues at GFI."", ""web_url"": ""https://dealbook.nytimes.com/2015/02/06/morning-agenda-radioshacks-bankruptcy-filing/"", ""snippet"": ""RadioShack files for bankruptcy. | Ally Financial is looking to ramp up performance. | Pfizer makes a big bet on a new class of generics. | Dysfunction continues at GFI."", ""lead_paragraph"": ""RADIOSHACK FILES FOR BANKRUPTCY | RadioShack has filed for bankruptcy, but is poised to live on in a diminished form, Rebecca R. Ruiz and Michael J. de la Merced report in DealBook. The Chapter 11 filing, in federal bankruptcy court in Delaware on Thursday, had long been expected for the 94-year-old electronics retailer, which has not been profitable since 2011. "", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Morning Agenda: RadioShack\u2019s Bankruptcy Filing"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [], ""pub_date"": ""2015-02-06T12:11:02+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Sydney Ember"", ""person"": [{""firstname"": ""Sydney"", ""middlename"": null, ""lastname"": ""Ember"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/de94c176-70e0-58d8-ab49-469dee2e3227"", ""word_count"": 2141, ""uri"": ""nyt://article/de94c176-70e0-58d8-ab49-469dee2e3227""}"
2015-03-20,"{""abstract"": ""The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials."", ""web_url"": ""https://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html"", ""snippet"": ""The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials."", ""lead_paragraph"": ""An experimental drug for Alzheimer\u2019s disease sharply slowed the decline in mental function in a small clinical trial, researchers reported Friday, reviving hopes for an approach to therapy that until now has experienced repeated failures."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Biogen Reports Its Alzheimer\u2019s Drug Sharply Slowed Cognitive Decline"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Alzheimer\u2019s Drug Shows Promise in a Trial"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Alzheimer's Disease"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Biogen Idec Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Dementia"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Eli Lilly and Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson & Johnson"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Roche Holding AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Nice (France)"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-03-20T09:34:55+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c8a818a6-fb97-57ec-b941-e937035b4b44"", ""word_count"": 999, ""uri"": ""nyt://article/c8a818a6-fb97-57ec-b941-e937035b4b44""}"
2015-04-27,"{""abstract"": ""Swedish Orphan Biovitrum, which makes the ReFacto AF treatment for hemophilia for Pfizer, received a preliminary offer from an undisclosed suitor."", ""web_url"": ""https://www.nytimes.com/2015/04/28/business/dealbook/swedish-orphan-biovitrum-deal.html"", ""snippet"": ""Swedish Orphan Biovitrum, which makes the ReFacto AF treatment for hemophilia for Pfizer, received a preliminary offer from an undisclosed suitor."", ""lead_paragraph"": ""LONDON \u2014 The biopharmaceutical maker Swedish Orphan Biovitrum said on Monday that it had received a preliminary takeover offer from an unnamed suitor."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Sobi, Swedish Maker of Drugs for Rare Diseases, Receives Takeover Bid"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Sobi Gets Offer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Swedish Orphan Biovitrum AB (Sobi)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-04-27T11:09:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/82fd7f59-5516-5686-86da-a8553865661c"", ""word_count"": 200, ""uri"": ""nyt://article/82fd7f59-5516-5686-86da-a8553865661c""}"
2015-06-02,"{""abstract"": ""If companies are going to fight activist investors who call for breakups or spinoffs, they should also be more honest about downsides of mergers."", ""web_url"": ""https://www.nytimes.com/2015/06/03/business/dealbook/breaking-up-companies-creates-extensive-costs-too.html"", ""snippet"": ""If companies are going to fight activist investors who call for breakups or spinoffs, they should also be more honest about downsides of mergers."", ""lead_paragraph"": ""Acquisitive corporate chieftains love to talk about \u201csynergies\u201d from the deals they\u2019re planning while they de-emphasize costs. On the flip side, managers who are trying to resist pressure to split their companies may overstate the \u201cdis-synergies\u201d such moves would create, but such costs are still real."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Breaking Up Companies Creates Extensive Costs, Too"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""JPMorgan Chase & Company"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}], ""pub_date"": ""2015-06-02T18:11:54+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran and Richard Beales"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Richard"", ""middlename"": null, ""lastname"": ""Beales"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1a6c5508-6c52-531b-add0-4c306893a29a"", ""word_count"": 371, ""uri"": ""nyt://article/1a6c5508-6c52-531b-add0-4c306893a29a""}"
2015-07-01,"{""abstract"": ""Four executives of leading health care organizations are members of the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to thwart antismoking laws."", ""web_url"": ""https://www.nytimes.com/2015/07/02/business/international/many-board-members-fight-smoking-even-as-chamber-opposes-tobacco-laws.html"", ""snippet"": ""Four executives of leading health care organizations are members of the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to thwart antismoking laws."", ""lead_paragraph"": ""Anthem, one of the nation\u2019s largest health insurers, wants its members to stop smoking."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/07/02/business/02smoke-web/02smoke-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/07/02/business/02smoke-web/02smoke-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""U.S. Chamber Fights Smoking Laws While Hospitals and Insurers Sit on Its Board"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Dissonance in Mission of Chamber on Tobacco"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Hakim, Danny"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hospitals"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Lobbying and Lobbyists"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Burson-Marsteller Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALTRIA GROUP INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Philip Morris Companies Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-07-01T09:00:07+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""International Business"", ""byline"": {""original"": ""By Danny Hakim"", ""person"": [{""firstname"": ""Danny"", ""middlename"": null, ""lastname"": ""Hakim"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/4402a9a6-9e32-5d5b-966e-2b676a3f06de"", ""word_count"": 1560, ""uri"": ""nyt://article/4402a9a6-9e32-5d5b-966e-2b676a3f06de""}"
2015-10-14,"{""abstract"": ""The Pfizer chemist helped create the antidepressant that has been used to treat more than 100 million people and has generated sales of more than $3 billion."", ""web_url"": ""https://www.nytimes.com/2015/10/14/business/kenneth-koe-co-inventor-behind-zoloft-dies-at-90.html"", ""snippet"": ""The Pfizer chemist helped create the antidepressant that has been used to treat more than 100 million people and has generated sales of more than $3 billion."", ""lead_paragraph"": ""Kenneth Koe, an inventor of Zoloft, the antidepressant that has helped tens of millions of people since it was introduced a quarter-century ago, died on Oct. 7 in Shrewsbury, Mass. He was 90."", ""print_section"": ""A"", ""print_page"": ""22"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-articleLarge.jpg"", ""height"": 413, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 413}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-jumbo.jpg"", ""height"": 705, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-superJumbo.jpg"", ""height"": 1409, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/14/business/11KOE-OBIT/11KOE-OBIT-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Kenneth Koe, an Inventor Behind Zoloft, Dies at 90"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Kenneth Koe, an Inventor Behind Zoloft, Dies at 90"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Deaths (Obituaries)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Fox, Margalit"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Zoloft (Drug)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Koe, Kenneth (1925-2015)"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2015-10-14T02:29:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Margalit Fox"", ""person"": [{""firstname"": ""Margalit"", ""middlename"": null, ""lastname"": ""Fox"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""Obituary (Obit)"", ""_id"": ""nyt://article/b8bcbe00-0de6-5369-aa77-89d929a68936"", ""word_count"": 555, ""uri"": ""nyt://article/b8bcbe00-0de6-5369-aa77-89d929a68936""}"
2015-10-29,"{""abstract"": ""Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine."", ""web_url"": ""https://www.nytimes.com/2015/10/30/business/dealbook/health-care-companies-in-merger-frenzy.html"", ""snippet"": ""Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine."", ""lead_paragraph"": ""In a fast-paced financial version of musical chairs, health care companies of all kinds \u2014 drug makers, hospital groups and insurers \u2014 have been frantically circling to be sure they are not left out of the latest frenzy of deal making. Mergers and acquisitions worth about $270 billion have been announced in the first nine months of 2015 in the United States, easily outpacing the activity in recent years, according to a tally by Mergermarket."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""height"": 508, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 508}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-jumbo.jpg"", ""height"": 867, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-superJumbo.jpg"", ""height"": 1253, ""width"": 1480, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/10/30/business/db-drug-web1/db-drug-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Health Care Companies in Merger Frenzy"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Health Care Companies, Seeking Scale, Are Caught Up in a Merger Frenzy"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Abelson, Reed"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Health Insurance and Managed Care"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Patient Protection and Affordable Care Act (2010)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hospitals"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-10-29T20:25:03+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Reed Abelson"", ""person"": [{""firstname"": ""Reed"", ""middlename"": null, ""lastname"": ""Abelson"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d"", ""word_count"": 1301, ""uri"": ""nyt://article/41d2a068-c7af-51e7-9203-2c8b0ce83a4d""}"
2015-11-04,"{""abstract"": ""In response Mylan\u2019s move to the Netherlands, the Securities and Exchange Commission now requires shareholder votes for each governance change from such deals."", ""web_url"": ""https://www.nytimes.com/2015/11/04/business/dealbook/regulators-unbundle-some-attractions-of-mergers.html"", ""snippet"": ""In response Mylan\u2019s move to the Netherlands, the Securities and Exchange Commission now requires shareholder votes for each governance change from such deals."", ""lead_paragraph"": ""The Securities and Exchange Commission has quietly taken a stand against corporate inversions. "", ""print_section"": ""B"", ""print_page"": ""4"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-jumbo.jpg"", ""height"": 1023, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-superJumbo.jpg"", ""height"": 1413, ""width"": 1414, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/04/business/04DEALPROF/04DEALPROF-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Regulators Unbundle Some Attractions of Mergers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Regulators Unbundle Some Attractions of Mergers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Securities and Exchange Commission"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Shareholder Rights and Activism"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Perrigo Company"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Chiquita Brands International Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Teva Pharmaceutical Industries Ltd"", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2015-11-04T01:37:14+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/da7da8d8-a9df-5016-92fe-0503e4d5f00b"", ""word_count"": 1016, ""uri"": ""nyt://article/da7da8d8-a9df-5016-92fe-0503e4d5f00b""}"
2015-11-06,"{""abstract"": ""The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases."", ""web_url"": ""https://www.nytimes.com/2015/11/07/business/dealbook/astrazeneca-agrees-to-buy-zs-pharma-for-2-7-billion.html"", ""snippet"": ""The transaction is expected to improve the British drug maker\u2019s pipeline of treatments for cardiovascular and metabolic diseases."", ""lead_paragraph"": ""LONDON \u2014 The British drug maker AstraZeneca said on Friday that it had agreed to acquire ZS Pharma, a California-based biopharmaceutical company, for $2.7 billion in cash."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Business Briefing; AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ZS Pharma Inc."", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2015-11-06T09:17:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8d30b7db-d7c6-5830-bba0-cb07a8de7dc7"", ""word_count"": 346, ""uri"": ""nyt://article/8d30b7db-d7c6-5830-bba0-cb07a8de7dc7""}"
2015-11-19,"{""abstract"": ""Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside."", ""web_url"": ""https://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html"", ""snippet"": ""Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside."", ""lead_paragraph"": ""Pfizer\u2019s $150 billion Botox gamble is a high-risk, low-benefit deal."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-11-19T19:12:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422"", ""word_count"": 389, ""uri"": ""nyt://article/09141cb3-72e2-5666-a4f6-4d41be980422""}"
2015-11-22,"{""abstract"": ""The deal, to be announced Monday, would create a huge new pharmaceutical giant and could potentially help Pfizer lower its American tax rate."", ""web_url"": ""https://www.nytimes.com/2015/11/23/business/dealbook/pfizer-and-allergan-reach-150-billion-merger-deal.html"", ""snippet"": ""The deal, to be announced Monday, would create a huge new pharmaceutical giant and could potentially help Pfizer lower its American tax rate."", ""lead_paragraph"": ""Pfizer has clinched a blockbuster merger with a fellow drug maker, one worth more than $150 billion, that can best be described in superlatives."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/23/business/23db-drug-web2/23db-drug-web2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Reach $150 Billion Merger Deal"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer Reaches Takeover Deal With Allergan "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Botox (Drug)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Relocation of Business"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2015-11-22T19:39:52+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e9d80199-98dc-58ff-a205-1ecae9ca9842"", ""word_count"": 1113, ""uri"": ""nyt://article/e9d80199-98dc-58ff-a205-1ecae9ca9842""}"
2015-11-23,"{""abstract"": ""With an equity value of $152 billion, the merger is the largest since the heady days of 2000."", ""web_url"": ""https://www.nytimes.com/2015/11/24/business/dealbook/how-the-pfizer-allergan-deal-ranks.html"", ""snippet"": ""With an equity value of $152 billion, the merger is the largest since the heady days of 2000."", ""lead_paragraph"": ""The huge price tag accorded to the deal between Allergan and Pfizer \u2014 $160 billion in total enterprise value \u2014 is one of the largest in history and the biggest ever among pharmaceutical companies."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg"", ""height"": 393, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 393}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-jumbo.jpg"", ""height"": 671, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-superJumbo.jpg"", ""height"": 1342, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24db-deal-web1/24db-deal-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""How the Pfizer-Allergan Deal Ranks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Vodafone Group Plc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mannesmann AG"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-11-23T18:49:32+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92"", ""word_count"": 275, ""uri"": ""nyt://article/47ec9b96-e47c-517c-9f8b-df52fc507d92""}"
2015-11-24,"{""abstract"": ""The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses."", ""web_url"": ""https://www.nytimes.com/2015/11/25/business/dealbook/pfizer-and-allergan-deal-comes-with-an-extensive-prenup.html"", ""snippet"": ""The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses."", ""lead_paragraph"": ""Pfizer and Allergan thought up several situations where their blockbuster $152 billion merger agreement could meet resistance, including from shareholders, regulators and lawmakers, and even rival suitors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""height"": 395, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 395}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-jumbo.jpg"", ""height"": 674, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-superJumbo.jpg"", ""height"": 1349, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/24DB-PFIZERjp2/24DB-PFIZERjp2-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer and Allergan Deal Comes With an Extensive Prenup"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Encounter (Magazine)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Franken, Al"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-11-24T22:36:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Liz Moyer"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Moyer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691"", ""word_count"": 577, ""uri"": ""nyt://article/6eb50ab5-1ef8-50bf-899a-ba279e013691""}"
2015-11-25,"{""abstract"": ""The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes."", ""web_url"": ""https://www.nytimes.com/2015/11/29/business/dealbook/pfizer-didnt-need-an-inversion-to-avoid-paying-us-taxes.html"", ""snippet"": ""The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes."", ""lead_paragraph"": ""Pfizer\u2019s declaration that it intends to merge with Allergan and cut taxes by moving its tax home to Dublin from New York City has set off something of a furor."", ""print_section"": ""BU"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg"", ""height"": 473, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/29/business/29-STRA/29-STRA-articleLarge-v2.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 473}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-jumbo-v2.jpg"", ""height"": 808, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-superJumbo-v2.jpg"", ""height"": 1615, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/29/business/29-STRA/29-STRA-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Didn\u2019t Need an Inversion to Avoid Paying U.S. Taxes"", ""kicker"": ""Strategies"", ""content_kicker"": null, ""print_headline"": ""The Benefits of Keeping Earnings in Exile"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2015-11-25T19:04:50+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Jeff Sommer"", ""person"": [{""firstname"": ""Jeff"", ""middlename"": null, ""lastname"": ""Sommer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f"", ""word_count"": 1127, ""uri"": ""nyt://article/83a0c8a3-2469-57ec-8a11-409f77e8169f""}"
2015-12-01,"{""abstract"": ""That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion."", ""web_url"": ""https://www.nytimes.com/2015/12/02/business/dealbook/pfizers-deal-for-allergan-is-a-dubious-milestone.html"", ""snippet"": ""That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion."", ""lead_paragraph"": ""Pfizer\u2019s $160 billion takeover of Allergan reached a few milestones in the mergers and acquisitions trade."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""height"": 443, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 443}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-jumbo.jpg"", ""height"": 757, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-superJumbo.jpg"", ""height"": 1478, ""width"": 2000, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/11/24/business/db-pfizerviews-web1/db-pfizerviews-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer\u2019s Deal for Allergan Is a Dubious Milestone"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2015-12-01T21:20:35+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Rob Cox"", ""person"": [{""firstname"": ""Rob"", ""middlename"": null, ""lastname"": ""Cox"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9"", ""word_count"": 875, ""uri"": ""nyt://article/508d18bc-31f1-59bb-99d4-174ac9e1ffe9""}"
2015-12-15,"{""abstract"": ""The exchange of business units would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""web_url"": ""https://www.nytimes.com/2015/12/16/business/dealbook/sanofi-boehringer-asset-swap.html"", ""snippet"": ""The exchange of business units would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""lead_paragraph"": ""LONDON \u2014 The French pharmaceutical company Sanofi and the German drug maker Boehringer Ingelheim said on Tuesday that they were in \u201cexclusive negotiations\u201d on a potential asset swap that would make Sanofi one of the world\u2019s largest manufacturers of nonprescription medicines."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-articleLarge.jpg"", ""height"": 337, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 337}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-jumbo.jpg"", ""height"": 574, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-superJumbo.jpg"", ""height"": 1149, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/16/business/16DB-Sanofi/16DB-Sanofi-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""European Drug Makers Sanofi and Boehringer Ingelheim in Talks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Two European Drug Makers in Talks About Asset Swaps"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Boehringer Ingelheim GmbH"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merial Animal Health"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Brandicourt, Olivier"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""France"", ""rank"": 10, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Germany"", ""rank"": 11, ""major"": ""N""}], ""pub_date"": ""2015-12-15T10:18:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/f40f6462-6b90-5091-ba69-d52bcfb464cb"", ""word_count"": 465, ""uri"": ""nyt://article/f40f6462-6b90-5091-ba69-d52bcfb464cb""}"
2015-12-17,"{""abstract"": ""The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector."", ""web_url"": ""https://www.nytimes.com/2015/12/18/business/dealbook/astrazeneca-to-acquire-majority-stake-in-acerta-pharma.html"", ""snippet"": ""The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector."", ""lead_paragraph"": ""LONDON \u2014 The British drug maker AstraZeneca said on Thursday that it had agreed to acquire a majority stake in Acerta Pharma, a privately-held cancer drug developer with operations in the Netherlands and in California, for $4 billion."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg"", ""height"": 376, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 376}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-jumbo.jpg"", ""height"": 642, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-superJumbo.jpg"", ""height"": 1283, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/18/world/18db-Astrazeneca-web/18db-Astrazeneca-web-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""AstraZeneca to Acquire Majority Stake in Acerta Pharma"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""AstraZeneca to Acquire Control of a Cancer Drug Developer"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Acerta Pharma BV"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Bray, Chad"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AstraZeneca PLC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Great Britain"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2015-12-17T09:37:53+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7"", ""word_count"": 393, ""uri"": ""nyt://article/abafa742-a66a-5faf-87c6-4b36c0e7c7c7""}"
2015-12-18,"{""abstract"": ""The British drug maker plans to acquire treatments at various stages of research in a deal with Bristol-Myers Squibb of New York that could be worth $1.46 billion."", ""web_url"": ""https://www.nytimes.com/2015/12/19/business/dealbook/gsk-bristol-myers-hiv.html"", ""snippet"": ""The British drug maker plans to acquire treatments at various stages of research in a deal with Bristol-Myers Squibb of New York that could be worth $1.46 billion."", ""lead_paragraph"": ""LONDON \u2014 GlaxoSmithKline said on Friday that it had agreed to acquire a pipeline of H.I.V. drugs in development from Bristol-Myers Squibb, in two deals that could be worth as much as $1.46 billion."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""GlaxoSmithKline to Buy Raft of H.I.V. Drugs in Development"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Acquired Immune Deficiency Syndrome"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bristol Myers Squibb Company"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""London (England)"", ""rank"": 7, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""Japan"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2015-12-18T11:50:51+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Chad Bray"", ""person"": [{""firstname"": ""Chad"", ""middlename"": null, ""lastname"": ""Bray"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/80e0e999-d0dd-5ac1-b4c8-0a58e01b5ab6"", ""word_count"": 204, ""uri"": ""nyt://article/80e0e999-d0dd-5ac1-b4c8-0a58e01b5ab6""}"
2015-12-22,"{""abstract"": ""The merger market is on track for a $4 trillion-plus year, and deal makers are no doubt celebrating, but this is also a time for reflection."", ""web_url"": ""https://www.nytimes.com/2015/12/23/business/dealbook/in-a-record-year-for-deals-success-and-a-few-missteps.html"", ""snippet"": ""The merger market is on track for a $4 trillion-plus year, and deal makers are no doubt celebrating, but this is also a time for reflection."", ""lead_paragraph"": ""It\u2019s time once again to hand out grades to the year\u2019s deals and deal makers."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-articleLarge.jpg"", ""height"": 600, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 600}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-jumbo.jpg"", ""height"": 1024, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-superJumbo.jpg"", ""height"": 1179, ""width"": 1179, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2015/12/23/business/23dealprof-illo/23dealprof-illo-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""In a Record Year for Deals, Success and a Few Missteps"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": ""In a Record Year for Deals, Success and a Few Missteps"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Shareholder Rights and Activism"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Boards of Directors"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""BGC Partners Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sysco Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GFI Group Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""House of Representatives"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Perrigo Company"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CIGNA Corporation"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AETNA INC"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mylan Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Royal Bank of Canada"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AIRGAS INC"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Senate"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 18, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Goldman Sachs Group Inc"", ""rank"": 19, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Federal Communications Commission"", ""rank"": 20, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hudson City Bancorp Inc"", ""rank"": 21, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AIR LIQUIDE SA"", ""rank"": 22, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pershing Square Capital Management"", ""rank"": 23, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Olive Garden Italian Restaurants"", ""rank"": 24, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Federal Trade Commission"", ""rank"": 25, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CME Group Inc"", ""rank"": 26, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 27, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""DuPont Co"", ""rank"": 28, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""CBS Corporation"", ""rank"": 29, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Humana Inc"", ""rank"": 30, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Comcast Corporation"", ""rank"": 31, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Starboard Value LP"", ""rank"": 32, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Square Inc"", ""rank"": 33, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Time Warner Cable Inc"", ""rank"": 34, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""US Foods Inc"", ""rank"": 35, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Valeant Pharmaceuticals International Inc"", ""rank"": 36, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Viacom Inc"", ""rank"": 37, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 38, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Dorsey, Jack"", ""rank"": 39, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Gooch, Michael A"", ""rank"": 40, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 41, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Redstone, Sumner M"", ""rank"": 42, ""major"": ""N""}], ""pub_date"": ""2015-12-22T20:29:06+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/ffe960da-0cc2-519f-9911-c97b81fcc96e"", ""word_count"": 1382, ""uri"": ""nyt://article/ffe960da-0cc2-519f-9911-c97b81fcc96e""}"
2016-01-05,"{""abstract"": ""The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent."", ""web_url"": ""https://www.nytimes.com/2016/01/06/business/sanofi-ends-marketing-deal-with-developer-of-inhaled-insulin.html"", ""snippet"": ""The insulin, called Afrezza, has had poor sales since being approved by the F.D.A. in 2014. Shares in its maker, MannKind, fell 48 percent."", ""lead_paragraph"": ""An inhaled insulin championed by a billionaire medical entrepreneur suffered a big setback on Tuesday when it was abandoned by the company with the rights to market it."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/06/business/06Insulin/06Insulin-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-superJumbo.jpg"", ""height"": 1367, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbStandard-v2.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/06/business/06Insulin/06Insulin-thumbLarge-v2.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Sanofi Ends Marketing Deal With Developer of Inhaled Insulin"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Shares of Inhaled Insulin Maker Plummet 48% as Big Marketing Partner Pulls Out"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Sanofi SA"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MannKind Corporation"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Mann, Alfred E"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Diabetes"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-01-05T18:05:34+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/1f3fccb0-77a0-591c-af2e-ccbebd991606"", ""word_count"": 914, ""uri"": ""nyt://article/1f3fccb0-77a0-591c-af2e-ccbebd991606""}"
2016-01-11,"{""abstract"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""web_url"": ""https://www.nytimes.com/2016/01/12/business/drug-companies-to-try-a-unified-front-against-cancer.html"", ""snippet"": ""Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs."", ""lead_paragraph"": ""SAN FRANCISCO \u2014 Some leading pharmaceutical companies are joining forces in an effort to speed the testing of new types of cancer drugs that harness the body\u2019s immune system to battle tumors."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""height"": 419, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 419}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-jumbo.jpg"", ""height"": 716, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-superJumbo.jpg"", ""height"": 1432, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/12/business/12cancer-web1/12cancer-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Drug Companies to Try a Unified Front Against Cancer"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Cancer"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Clinical Trials"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Soon-Shiong, Patrick"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMGEN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Celgene Corporation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""GlaxoSmithKline PLC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Merck & Company Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-01-11T15:46:36+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f"", ""word_count"": 505, ""uri"": ""nyt://article/e37fcae4-ae54-52e9-923d-774b4b8ee48f""}"
2016-01-13,"{""abstract"": ""When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest."", ""web_url"": ""https://www.nytimes.com/2016/01/14/business/hemophilia-patient-or-drug-seller-dual-role-creates-ethical-quandary.html"", ""snippet"": ""When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest."", ""lead_paragraph"": ""LaQuenta Caldwell-Moody considered it improper when a pharmacy sales representative tried to take her teenage son, when he was still a minor, to dinner without her."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-articleLarge.jpg"", ""height"": 398, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 398}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-jumbo.jpg"", ""height"": 680, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-superJumbo.jpg"", ""height"": 1360, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/14/business/14hemophilia-web1/14hemophilia-web1-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""The Patient&#8217;s Sales Pitch "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Pollack, Andrew"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hemophilia"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Conflicts of Interest"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Blood"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Ethics and Official Misconduct"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hemophilia of North Carolina"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""National Hemophilia Foundation"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""MedfusionRx LLC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Bayer AG"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Novo Nordisk A/S"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baxalta Inc."", ""rank"": 13, ""major"": ""N""}], ""pub_date"": ""2016-01-13T18:17:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Andrew Pollack"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": null, ""lastname"": ""Pollack"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9b1396b3-f5a4-506f-9b88-5c157864f836"", ""word_count"": 1254, ""uri"": ""nyt://article/9b1396b3-f5a4-506f-9b88-5c157864f836""}"
2016-01-26,"{""abstract"": ""Johnson Controls is just the latest corporation to flee America for greener, lower-tax pastures. And until lawmakers reform the tax code, the exodus will continue."", ""web_url"": ""https://www.nytimes.com/2016/01/26/business/dealbook/a-tidal-wave-of-corporate-migrants-seeking-tax-shelter.html"", ""snippet"": ""Johnson Controls is just the latest corporation to flee America for greener, lower-tax pastures. And until lawmakers reform the tax code, the exodus will continue."", ""lead_paragraph"": ""In the fall of 2008, with General Motors and Chrysler on the precipice of bankruptcy, executives at the car parts supplier Johnson Controls flew to Washington. The company\u2019s president testified before a Senate panel and implored lawmakers to bail out the auto industry."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-articleLarge.jpg"", ""height"": 417, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 417}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-jumbo.jpg"", ""height"": 711, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-superJumbo.jpg"", ""height"": 1329, ""width"": 1913, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/01/26/business/26subSORKIN/26subSORKIN-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter"", ""kicker"": ""DealBook"", ""content_kicker"": null, ""print_headline"": ""A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Sorkin, Andrew Ross"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Johnson Controls Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporations"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Tyco International Co"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medtronic Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Coca-Cola Company"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-01-26T01:23:09+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Andrew Ross Sorkin"", ""person"": [{""firstname"": ""Andrew"", ""middlename"": ""Ross"", ""lastname"": ""Sorkin"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/26bf6a9f-690b-5deb-bc0c-2ac27d1367cd"", ""word_count"": 833, ""uri"": ""nyt://article/26bf6a9f-690b-5deb-bc0c-2ac27d1367cd""}"
2016-02-10,"{""abstract"": ""The bigger benefit to corporations fleeing American tax bills \u2014 and the bigger loss to American taxpayers \u2014 is a maneuver called earnings stripping."", ""web_url"": ""https://www.nytimes.com/2016/02/10/business/dealbook/corporate-inversions-arent-the-half-of-it.html"", ""snippet"": ""The bigger benefit to corporations fleeing American tax bills \u2014 and the bigger loss to American taxpayers \u2014 is a maneuver called earnings stripping."", ""lead_paragraph"": ""If you thought there was a problem with inversions \u2014 deals that allow American companies to relocate their headquarters to lower their tax bills \u2014 wait until you hear about the real secret to avoiding corporate taxes. It\u2019s called earnings stripping, and it is a technique that the Obama administration has so far failed to stop."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-articleLarge.jpg"", ""height"": 602, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 602}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-jumbo.jpg"", ""height"": 1024, ""width"": 1022, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-superJumbo.jpg"", ""height"": 1194, ""width"": 1191, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/10/business/10DEALPROF/10DEALPROF-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Corporate Inversions Aren\u2019t the Half of It"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": ""If You Think Corporate Inversions Are Bad, Brace Yourself"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Federal Taxes (US)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""United States Politics and Government"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 7, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-02-10T00:40:40+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/544f37bf-7ed2-5d53-b69c-1e9d6472fda5"", ""word_count"": 1068, ""uri"": ""nyt://article/544f37bf-7ed2-5d53-b69c-1e9d6472fda5""}"
2016-02-19,"{""abstract"": ""If Burger King and Pfizer can lower their tax rates with inversions, why can\u2019t I?"", ""web_url"": ""https://www.nytimes.com/2016/02/21/business/yourtaxes/just-send-the-tax-bill-to-my-personal-irish-subsidiary.html"", ""snippet"": ""If Burger King and Pfizer can lower their tax rates with inversions, why can\u2019t I?"", ""lead_paragraph"": ""I want to lower my taxes. It\u2019s one of my dreams, along with becoming taller. And younger. And much, much richer."", ""print_section"": ""BU"", ""print_page"": ""9"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-articleLarge.jpg"", ""height"": 466, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/02/21/business/21ESSAY/21ESSAY-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 466}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-jumbo.jpg"", ""height"": 796, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-superJumbo.jpg"", ""height"": 1592, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/02/21/business/21ESSAY/21ESSAY-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Just Send the Tax Bill to My Personal Irish Subsidiary"", ""kicker"": ""2016 Taxes | Essay"", ""content_kicker"": null, ""print_headline"": ""Just Send the Tax Bill to My Personal Irish Subsidiary  "", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Income Tax"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 8, ""major"": ""N""}], ""pub_date"": ""2016-02-19T21:16:56+0000"", ""document_type"": ""article"", ""news_desk"": ""SundayBusiness"", ""section_name"": ""Business Day"", ""subsection_name"": ""Your Taxes"", ""byline"": {""original"": ""By John Schwartz"", ""person"": [{""firstname"": ""John"", ""middlename"": null, ""lastname"": ""Schwartz"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""An Analysis"", ""_id"": ""nyt://article/e587fc2f-52bb-5bfd-88f8-632544549a02"", ""word_count"": 1168, ""uri"": ""nyt://article/e587fc2f-52bb-5bfd-88f8-632544549a02""}"
2016-04-05,"{""abstract"": ""The broader reach of regulations, intended to keep companies from cutting deals to move income overseas, appears to have caught many by surprise."", ""web_url"": ""https://www.nytimes.com/2016/04/06/business/dealbook/tax-inversion-obama-treasury.html"", ""snippet"": ""The broader reach of regulations, intended to keep companies from cutting deals to move income overseas, appears to have caught many by surprise."", ""lead_paragraph"": ""Pfizer plans to abandon its $152 billion merger with Allergan \u2014 the largest deal yet aimed at helping an American company shed its United States corporate citizenship for a lower tax bill \u2014 just days after the Obama administration introduced new tax rules, a person briefed on the matter said late Tuesday."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer and Allergan Are Said to End Merger as Tax Rules Tighten"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Pfizer and Allergan Said to End Merger as Tax Rules Tighten"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Obama, Barack"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Law and Legislation"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 10, ""major"": ""N""}], ""pub_date"": ""2016-04-05T17:06:05+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced and Leslie Picker"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/3e04673c-6e25-5bc3-880a-50110b786db6"", ""word_count"": 1458, ""uri"": ""nyt://article/3e04673c-6e25-5bc3-880a-50110b786db6""}"
2016-04-06,"{""abstract"": ""In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility."", ""web_url"": ""https://www.nytimes.com/2016/04/07/business/dealbook/finger-pointing-abounds-in-failed-pfizer-deal.html"", ""snippet"": ""In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility."", ""lead_paragraph"": ""Pfizer\u2019s abandoned deal leaves all sides tainted."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Finger-Pointing Abounds in Failed Pfizer Deal"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-06T19:19:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/db227162-6882-5514-8d8d-3286bb786631"", ""word_count"": 366, ""uri"": ""nyt://article/db227162-6882-5514-8d8d-3286bb786631""}"
2016-04-07,"{""abstract"": ""The government\u2019s crackdown on inversions and two lawsuits it filed this week offer some things for advisers, companies and shareholders to think about."", ""web_url"": ""https://www.nytimes.com/2016/04/08/business/dealbook/lessons-in-a-busy-week-of-deal-busting.html"", ""snippet"": ""The government\u2019s crackdown on inversions and two lawsuits it filed this week offer some things for advisers, companies and shareholders to think about."", ""lead_paragraph"": ""Corporate America fought the law and the law won."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg"", ""height"": 608, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 608}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-jumbo.jpg"", ""height"": 1024, ""width"": 1011, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-superJumbo.jpg"", ""height"": 1225, ""width"": 1209, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/03/29/business/0329dealprofjpg/0329dealprofjpg-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Lessons in a Busy Week of Deal Busting"", ""kicker"": ""Deal Professor"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-07T21:29:18+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Steven Davidoff Solomon"", ""person"": [{""firstname"": ""Steven"", ""middlename"": ""Davidoff"", ""lastname"": ""Solomon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/87d505c0-28f1-56d0-b494-9dbf5e2878e0"", ""word_count"": 1106, ""uri"": ""nyt://article/87d505c0-28f1-56d0-b494-9dbf5e2878e0""}"
2016-04-14,"{""abstract"": ""Companies are abandoning the biggest mergers, largely out of concern over how the government might react in an election year."", ""web_url"": ""https://www.nytimes.com/2016/04/15/business/dealbook/the-winds-from-washington-chill-wall-streets-deal-making.html"", ""snippet"": ""Companies are abandoning the biggest mergers, largely out of concern over how the government might react in an election year."", ""lead_paragraph"": ""On Wall Street, the phones have been a little quieter. The workload has been a little lighter. The happy hours have been starting earlier."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-articleLarge.jpg"", ""height"": 401, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/15/business/15db-mergers/15db-mergers-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 401}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-jumbo.jpg"", ""height"": 684, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-superJumbo.jpg"", ""height"": 1368, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/15/business/15db-mergers/15db-mergers-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""The Winds From Washington Chill Wall Street\u2019s Deal Making"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Winds From Washington Chill the Biggest Deals of Wall Street\u2019s Making"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Justice Department"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}], ""pub_date"": ""2016-04-14T19:58:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/a33bbc92-a853-5cca-bd09-063689768d9a"", ""word_count"": 872, ""uri"": ""nyt://article/a33bbc92-a853-5cca-bd09-063689768d9a""}"
2016-05-05,"{""abstract"": ""As the drug-giant weighs its options, setting a strategy would be better than keeping all doors open."", ""web_url"": ""https://www.nytimes.com/2016/05/06/business/dealbook/pfizer-needs-clearer-goals.html"", ""snippet"": ""As the drug-giant weighs its options, setting a strategy would be better than keeping all doors open."", ""lead_paragraph"": ""Pfizer\u2019s record with mergers hardly inspires confidence. The drug giant\u2019s last two huge acquisition attempts failed. It could try another merger to cut its tax rate, it could enter one or more potentially heated auctions or it could split up. If it wants to succeed at deal making, the company needs clearer goals."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Needs Clearer Goals"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-05-05T17:19:21+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8935f33d-0066-5e18-af7a-a4c46773c744"", ""word_count"": 324, ""uri"": ""nyt://article/8935f33d-0066-5e18-af7a-a4c46773c744""}"
2016-05-10,"{""abstract"": ""The recent actions of Zoetis and Allergan suggest a more subdued approach to deals."", ""web_url"": ""https://www.nytimes.com/2016/05/11/business/dealbook/change-is-in-the-air-for-pharmaceutical-mergers.html"", ""snippet"": ""The recent actions of Zoetis and Allergan suggest a more subdued approach to deals."", ""lead_paragraph"": ""The pharmaceuticals merger mind-set may be changing. Allergan, the $87 billion maker of Botox, will devote capital to stock buybacks and paying down debt."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Change Is in the Air for Pharmaceutical Mergers"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Zoetis Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Ackman, William A"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2016-05-10T23:01:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/cc677553-4c1d-5703-b5df-7df222697f8a"", ""word_count"": 386, ""uri"": ""nyt://article/cc677553-4c1d-5703-b5df-7df222697f8a""}"
2016-05-12,"{""abstract"": ""Since the beginning of January, $400 billion worth of corporate mergers have fallen apart in the United States, creating anxiety in those who bet on them."", ""web_url"": ""https://www.nytimes.com/2016/05/12/business/dealbook/hedge-funds-look-for-hard-hats-in-a-year-of-collapsing-mergers.html"", ""snippet"": ""Since the beginning of January, $400 billion worth of corporate mergers have fallen apart in the United States, creating anxiety in those who bet on them."", ""lead_paragraph"": ""While last year set a record for the amount of money spent on corporate mergers \u2014 $4.7 trillion \u2014 this year is so far setting a very different record: the dollar amount of deals that have come undone."", ""print_section"": ""A"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/05/12/business/11DB-ARBS/11DB-ARBS-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Hedge Funds Look for Hard Hats in a Year of Collapsing Mergers"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": "" Hedge Funds Reach for Hard Hats in Year of Collapsing Mergers"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Hedge Funds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Dealogic PLC"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-05-12T00:52:29+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/c773f09f-15e2-558b-8d18-91023d22370f"", ""word_count"": 1275, ""uri"": ""nyt://article/c773f09f-15e2-558b-8d18-91023d22370f""}"
2016-05-16,"{""abstract"": ""The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""web_url"": ""https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-could-get-its-moneys-worth-out-of-anacor-deal.html"", ""snippet"": ""The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""lead_paragraph"": ""Pfizer\u2019s $5.2 billion offer for Anacor Pharmaceuticals, announced on Monday, dodges the drug giant\u2019s bigger issue. The company may have made a good deal for Anacor, the maker of eczema and toenail-fungus remedies, even though it\u2019s paying a 55 percent premium. The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Pfizer Could Get Its Money\u2019s Worth Out of Anacor Deal"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Anacor Pharmaceuticals Inc"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-05-16T18:31:45+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Antony Currie"", ""person"": [{""firstname"": ""Antony"", ""middlename"": null, ""lastname"": ""Currie"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5"", ""word_count"": 363, ""uri"": ""nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5""}"
2016-05-31,"{""abstract"": ""Months ago, Mr. Icahn criticized Pfizer\u2019s proposed takeover of Allergan; now he is buying part of the company."", ""web_url"": ""https://www.nytimes.com/2016/06/01/business/dealbook/carl-icahn-takes-stake-in-allergan.html"", ""snippet"": ""Months ago, Mr. Icahn criticized Pfizer\u2019s proposed takeover of Allergan; now he is buying part of the company."", ""lead_paragraph"": ""Five months ago, Carl C. Icahn deplored Pfizer\u2019s proposed takeover of the Ireland-based drug maker Allergan as a \u201ctravesty\u201d meant to help one of America\u2019s biggest companies lower its tax bill by moving abroad."", ""print_section"": ""B"", ""print_page"": ""2"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-articleLarge.jpg"", ""height"": 399, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/06/01/business/01db-allergen/01db-allergen-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 399}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-superJumbo.jpg"", ""height"": 1363, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/06/01/business/01db-allergen/01db-allergen-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Carl Icahn Takes Stake in Allergan"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""After Blasting Pfizer\u2019s Plan, Icahn Buys Allergan Stake"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""de la Merced, Michael J"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Icahn, Carl C"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Forest Laboratories Inc"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-05-31T20:17:39+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dae93f6c-dc91-5a43-aa7a-ca8286ae0350"", ""word_count"": 388, ""uri"": ""nyt://article/dae93f6c-dc91-5a43-aa7a-ca8286ae0350""}"
2016-07-07,"{""abstract"": ""The Treasury Department wants to curb a practice called earnings stripping, but its efforts could hurt normal funding practices."", ""web_url"": ""https://www.nytimes.com/2016/07/08/business/dealbook/plan-to-curb-tax-inversion-deals-could-go-too-far.html"", ""snippet"": ""The Treasury Department wants to curb a practice called earnings stripping, but its efforts could hurt normal funding practices."", ""lead_paragraph"": ""There\u2019s a harmful flip side to the push against tax-inversion deals in the United States. The Treasury Department\u2019s latest plan to curb tax-motivated overseas mergers takes aim at inter-company loans. It is a good idea to curb this so-called earnings stripping. The proposed rule is broad, however, and could hurt normal funding practices."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Plan to Curb Tax-Inversion Deals Could Go Too Far"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-07-07T17:48:08+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Gina Chon"", ""person"": [{""firstname"": ""Gina"", ""middlename"": null, ""lastname"": ""Chon"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/9f4729c2-8ab1-53cf-99a1-a3e32e328fc4"", ""word_count"": 403, ""uri"": ""nyt://article/9f4729c2-8ab1-53cf-99a1-a3e32e328fc4""}"
2016-08-04,"{""abstract"": ""The Chamber is leading a legal fight in Texas to overturn Treasury rules aimed at curbing mergers done for tax reasons."", ""web_url"": ""https://www.nytimes.com/2016/08/05/business/dealbook/tax-avoiding-mergers-find-champion-in-us-chamber-of-commerce.html"", ""snippet"": ""The Chamber is leading a legal fight in Texas to overturn Treasury rules aimed at curbing mergers done for tax reasons."", ""lead_paragraph"": ""The U.S. Chamber of Commerce filed a lawsuit on Thursday to block new rules issued by the Obama administration that prevent American corporations from merging with foreign-based companies and moving their headquarters abroad to save on taxes."", ""print_section"": ""B"", ""print_page"": ""3"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/05/business/05DB-INVERSIONS/05DB-INVERSIONS-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Tax-Avoiding Mergers Find Champion in U.S. Chamber of Commerce"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Texas Suit Would Keep Tax Strategy Deals Legal"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 1, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 2, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Moyer, Liz"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Suits and Litigation (Civil)"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Regulation and Deregulation of Industry"", ""rank"": 5, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 10, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Shelters"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Internal Revenue Service"", ""rank"": 12, ""major"": ""N""}], ""pub_date"": ""2016-08-04T23:35:19+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Liz Moyer and Leslie Picker"", ""person"": [{""firstname"": ""Liz"", ""middlename"": null, ""lastname"": ""Moyer"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}, {""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 2}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/b9b359f8-dde7-5f46-adab-e67ad6e68c40"", ""word_count"": 689, ""uri"": ""nyt://article/b9b359f8-dde7-5f46-adab-e67ad6e68c40""}"
2016-08-22,"{""abstract"": ""A heated auction and back-of-the-envelope math hint that the buyer is overpaying."", ""web_url"": ""https://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html"", ""snippet"": ""A heated auction and back-of-the-envelope math hint that the buyer is overpaying."", ""lead_paragraph"": ""Pfizer seems to know something others do not about the biotech company Medivation."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""The Flaws in Pfizer\u2019s Plan to Acquire Medivation"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 1, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Astellas Pharma"", ""rank"": 5, ""major"": ""N""}], ""pub_date"": ""2016-08-22T20:05:15+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b"", ""word_count"": 376, ""uri"": ""nyt://article/dcca7dbf-9072-50c6-a62d-162fd6851b1b""}"
2016-08-23,"{""abstract"": ""Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits."", ""web_url"": ""https://www.nytimes.com/2016/08/23/business/dealbook/oil-refinery-pfizer-medivation-viacom.html"", ""snippet"": ""Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits."", ""lead_paragraph"": ""\u201cIt\u2019s a black pool of speculation that could cause bankruptcies in our sector.\u201d"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-jumbo.jpg"", ""height"": 683, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/08/23/business/23db-newsletter/23db-newsletter-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Morning Agenda: Prices of Ethanol Credits Surge, Hurting Oil Refiners"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Oil (Petroleum) and Gasoline"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Alternative and Renewable Energy"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Viacom Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Medivation Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Redstone, Sumner M"", ""rank"": 7, ""major"": ""N""}], ""pub_date"": ""2016-08-23T10:00:12+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Amie Tsang"", ""person"": [{""firstname"": ""Amie"", ""middlename"": null, ""lastname"": ""Tsang"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/8680ef31-789a-5474-a5e3-fdac07bc01c7"", ""word_count"": 546, ""uri"": ""nyt://article/8680ef31-789a-5474-a5e3-fdac07bc01c7""}"
2016-09-26,"{""abstract"": ""Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up."", ""web_url"": ""https://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html"", ""snippet"": ""Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up."", ""lead_paragraph"": ""Pfizer has finally admitted that there is no rabbit in its breakup hat."", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""height"": 400, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 400}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-jumbo.jpg"", ""height"": 682, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-superJumbo.jpg"", ""height"": 1365, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}], ""headline"": {""main"": ""Pfizer Remains Whole, but the Option to Split Could Return"", ""kicker"": ""Breakingviews"", ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Drugs (Pharmaceuticals)"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 3, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Read, Ian C"", ""rank"": 4, ""major"": ""N""}], ""pub_date"": ""2016-09-26T17:44:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Robert Cyran"", ""person"": [{""firstname"": ""Robert"", ""middlename"": null, ""lastname"": ""Cyran"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624"", ""word_count"": 396, ""uri"": ""nyt://article/598f42d1-4e8a-56c9-9783-fba1887a4624""}"
2016-10-13,"{""abstract"": ""Part of the Treasury\u2019s goal was to clamp down on earnings stripping. But many multinationals with no history of inversions were affected by the rules as well."", ""web_url"": ""https://www.nytimes.com/2016/10/14/business/dealbook/exemptions-made-to-treasurys-tax-saving-restriction-rules.html"", ""snippet"": ""Part of the Treasury\u2019s goal was to clamp down on earnings stripping. But many multinationals with no history of inversions were affected by the rules as well."", ""lead_paragraph"": ""After the Treasury Department announced new rules in April restricting companies from using certain tax-reduction strategies, the protests rang out loudly. Business lobbying groups, executives, tax experts and lawmakers argued that they went too far."", ""print_section"": ""B"", ""print_page"": ""6"", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""Companies Hurt by Treasury Crackdown Win Exemptions"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Firms Hurt by Crackdown by Treasury Win Pardons"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""persons"", ""value"": ""Picker, Leslie"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Tax Credits, Deductions and Exemptions"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Business Roundtable"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United States Chamber of Commerce"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Treasury Department"", ""rank"": 7, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Lew, Jacob J"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Taxes"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-10-13T23:49:49+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Leslie Picker"", ""person"": [{""firstname"": ""Leslie"", ""middlename"": null, ""lastname"": ""Picker"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/608169b2-de99-58d4-a2f4-b439f24852b5"", ""word_count"": 507, ""uri"": ""nyt://article/608169b2-de99-58d4-a2f4-b439f24852b5""}"
2016-11-06,"{""abstract"": ""Proposition 56 would tax e-cigarettes in the state for the first time, despite evidence suggesting e-cigarettes are less harmful and may help people quit smoking."", ""web_url"": ""https://www.nytimes.com/2016/11/07/business/debate-over-risk-of-e-cigarettes-plays-out-on-california-ballot.html"", ""snippet"": ""Proposition 56 would tax e-cigarettes in the state for the first time, despite evidence suggesting e-cigarettes are less harmful and may help people quit smoking."", ""lead_paragraph"": ""Wearing a white lab coat, the doctor looks straight at the camera and explains why Californians should vote against higher taxes on tobacco products."", ""print_section"": ""B"", ""print_page"": ""5"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbStandard-v4.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbStandard-v4.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-thumbLarge-v4.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-articleLarge-v3.jpg"", ""height"": 389, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-articleLarge-v3.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 389}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-jumbo-v3.jpg"", ""height"": 664, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/11/05/business/00ECIG2-sub/00ECIG2-sub-superJumbo-v3.jpg"", ""height"": 1327, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Who Wins if California Voters Tax E-Cigarettes?"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""California Voters to Have a Say on an E-Cigarette Tax"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Smoking and Tobacco"", ""rank"": 2, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""E-Cigarettes"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Referendums"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Taxation"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALTRIA GROUP INC"", ""rank"": 6, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Reynolds, R J, Tobacco Co"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Philip Morris Companies Inc"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""AMERICAN LUNG ASSN"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Food and Drug Administration"", ""rank"": 11, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Glantz, Stanton A"", ""rank"": 12, ""major"": ""N""}, {""name"": ""glocations"", ""value"": ""California"", ""rank"": 13, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Sales and Excise Taxes"", ""rank"": 14, ""major"": ""N""}], ""pub_date"": ""2016-11-06T21:29:24+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""byline"": {""original"": ""By Rachel Abrams"", ""person"": [{""firstname"": ""Rachel"", ""middlename"": null, ""lastname"": ""Abrams"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/12f2a597-c57e-526f-bf4f-eaf6190ad0f5"", ""word_count"": 1106, ""uri"": ""nyt://article/12f2a597-c57e-526f-bf4f-eaf6190ad0f5""}"
2016-12-15,"{""abstract"": ""MSCI\u2019s social index business grows as big pensions and other investors pour money into funds that focus on more than just corporate balance sheets."", ""web_url"": ""https://www.nytimes.com/2016/12/14/business/dealbook/investors-social-environmental-corporate-governance.html"", ""snippet"": ""MSCI\u2019s social index business grows as big pensions and other investors pour money into funds that focus on more than just corporate balance sheets."", ""lead_paragraph"": ""Pfizer stock was riding high in June 2015, up 128 percent in five years, making it the second-most valuable American drug maker. Nine out of 10 Wall Street research analysts recommended that investors hold it in their portfolio, if not buy more."", ""print_section"": ""B"", ""print_page"": ""1"", ""source"": ""The New York Times"", ""multimedia"": [{""rank"": 0, ""subtype"": ""thumbnail"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbStandard.jpg"", ""height"": 75, ""width"": 75, ""subType"": ""thumbnail"", ""crop_name"": ""thumbStandard"", ""legacy"": {""thumbnail"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbStandard.jpg"", ""thumbnailwidth"": 75, ""thumbnailheight"": 75}}, {""rank"": 0, ""subtype"": ""thumbLarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-thumbLarge.jpg"", ""height"": 150, ""width"": 150, ""subType"": ""thumbLarge"", ""crop_name"": ""thumbLarge"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""xlarge"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-articleLarge.jpg"", ""height"": 474, ""width"": 600, ""subType"": ""xlarge"", ""crop_name"": ""articleLarge"", ""legacy"": {""xlarge"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-articleLarge.jpg"", ""xlargewidth"": 600, ""xlargeheight"": 474}}, {""rank"": 0, ""subtype"": ""jumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-jumbo.jpg"", ""height"": 810, ""width"": 1024, ""subType"": ""jumbo"", ""crop_name"": ""jumbo"", ""legacy"": {}}, {""rank"": 0, ""subtype"": ""superJumbo"", ""caption"": null, ""credit"": null, ""type"": ""image"", ""url"": ""images/2016/12/14/business/14DB-SOCIAL/14DB-SOCIAL-superJumbo.jpg"", ""height"": 1619, ""width"": 2048, ""subType"": ""superJumbo"", ""crop_name"": ""superJumbo"", ""legacy"": {}}], ""headline"": {""main"": ""Investors Sharpen Focus on Social and Environmental Risks to Stocks"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": ""Investor Demand Leads Analysts to Focus on Stocks\u2019 Social and Environmental Risks"", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""organizations"", ""value"": ""MSCI Inc"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Stocks and Bonds"", ""rank"": 3, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Research"", ""rank"": 4, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Environment"", ""rank"": 6, ""major"": ""N""}, {""name"": ""persons"", ""value"": ""Monks, Robert A G"", ""rank"": 8, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Corporate Social Responsibility"", ""rank"": 9, ""major"": ""N""}], ""pub_date"": ""2016-12-15T01:15:43+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Randall Smith"", ""person"": [{""firstname"": ""Randall"", ""middlename"": null, ""lastname"": ""Smith"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/aec807e7-8260-55c1-a5d9-59ef3ff41459"", ""word_count"": 1229, ""uri"": ""nyt://article/aec807e7-8260-55c1-a5d9-59ef3ff41459""}"
2016-12-26,"{""abstract"": ""Big takeovers by the likes of the pharmaceutical giant Pfizer, the Oreos maker Mondelez and the office supply retailer Staples were all consigned to the scrap heap."", ""web_url"": ""https://www.nytimes.com/2016/12/26/business/dealbook/more-than-1000-deals-were-abandoned-in-2016.html"", ""snippet"": ""Big takeovers by the likes of the pharmaceutical giant Pfizer, the Oreos maker Mondelez and the office supply retailer Staples were all consigned to the scrap heap."", ""lead_paragraph"": ""It may not have been a banner year for striking deals, but 2016 was a healthy time for breaking them."", ""source"": ""The New York Times"", ""multimedia"": [], ""headline"": {""main"": ""2016 Was a Year for Undoing Major Deals"", ""kicker"": null, ""content_kicker"": null, ""print_headline"": """", ""name"": null, ""seo"": null, ""sub"": null}, ""keywords"": [{""name"": ""subject"", ""value"": ""Two Thousand Sixteen"", ""rank"": 1, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Mergers, Acquisitions and Divestitures"", ""rank"": 2, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""ALLERGAN INC"", ""rank"": 3, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Honeywell International Inc"", ""rank"": 4, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Monsanto Company"", ""rank"": 5, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Pfizer Inc"", ""rank"": 6, ""major"": ""N""}, {""name"": ""subject"", ""value"": ""Antitrust Laws and Competition Issues"", ""rank"": 7, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""United Technologies Corporation"", ""rank"": 8, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Energy Transfer Equity LP"", ""rank"": 9, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Williams Companies Inc"", ""rank"": 10, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Halliburton Company"", ""rank"": 11, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Baker Hughes Inc"", ""rank"": 12, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Mondelez International Inc"", ""rank"": 13, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Hershey Foods Corp"", ""rank"": 14, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Anbang Insurance Group Co"", ""rank"": 15, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Starwood Hotels & Resorts Worldwide Inc"", ""rank"": 16, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Staples Inc"", ""rank"": 17, ""major"": ""N""}, {""name"": ""organizations"", ""value"": ""Office Depot Inc."", ""rank"": 18, ""major"": ""N""}], ""pub_date"": ""2016-12-26T20:03:50+0000"", ""document_type"": ""article"", ""news_desk"": ""Business"", ""section_name"": ""Business Day"", ""subsection_name"": ""DealBook"", ""byline"": {""original"": ""By Michael J. de la Merced"", ""person"": [{""firstname"": ""Michael"", ""middlename"": ""J."", ""lastname"": ""de la Merced"", ""qualifier"": null, ""title"": null, ""role"": ""reported"", ""organization"": """", ""rank"": 1}], ""organization"": null}, ""type_of_material"": ""News"", ""_id"": ""nyt://article/85b6d2d9-fd58-5c73-8a78-7c70431c1e83"", ""word_count"": 1012, ""uri"": ""nyt://article/85b6d2d9-fd58-5c73-8a78-7c70431c1e83""}"
